US9618508B2 - Flow cytometry analysis of materials adsorbed to metal salts - Google Patents

Flow cytometry analysis of materials adsorbed to metal salts Download PDF

Info

Publication number
US9618508B2
US9618508B2 US13/994,536 US201113994536A US9618508B2 US 9618508 B2 US9618508 B2 US 9618508B2 US 201113994536 A US201113994536 A US 201113994536A US 9618508 B2 US9618508 B2 US 9618508B2
Authority
US
United States
Prior art keywords
adsorbed
component
metal salt
insoluble metal
aluminium hydroxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US13/994,536
Other versions
US20130330840A1 (en
Inventor
David Skibinski
Donatello Laera
Sandra Nuti
Mildred Ugozzoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to US13/994,536 priority Critical patent/US9618508B2/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, S.R.L. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NUTI, SANDRA, SKIBINSKI, DAVID, LAERA, DONATELLA
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UGOZZOLI, MILDRED
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS VACCINES AND DIAGNOSTICS, S.R.L.
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Publication of US20130330840A1 publication Critical patent/US20130330840A1/en
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA reassignment GLAXOSMITHKLINE BIOLOGICALS SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS AG
Application granted granted Critical
Publication of US9618508B2 publication Critical patent/US9618508B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Definitions

  • the invention is in the field of analysing adsorbed material e.g. in vaccines.
  • Vaccine antigens are frequently adsorbed to insoluble metal salts, such as aluminium hydroxide and aluminium phosphate, to provide an adjuvant effect. It is often necessary to analyse antigens after their adsorption, but the adsorption itself can make analysis difficult e.g. as described in reference 1 for hepatitis B surface antigen (HBsAg).
  • insoluble metal salts such as aluminium hydroxide and aluminium phosphate
  • DFIA direct alhydrogel formulation immunoassay
  • the invention utilises the techniques and instruments which are typically used in flow cytometry (FC) as a tool for analysing adsorbed materials.
  • FC flow cytometry
  • the invention provides in general a convenient way of analysing adsorbed components, which permits the analysis of individual particles of insoluble metal salts with components adsorbed to them to determine their properties, and from there to determine the average properties of a suspension of these particles.
  • a suspension of insoluble metal salt particles with adsorbed component(s) is passed through a flow cytometer to determine the properties of the individual particles.
  • each particle is passed through one or more beams of light, typically laser beams of set wavelength.
  • a number of detectors are placed around the beam(s) of light. One detector is in line with the light beam in order to detect the forward scatter, and one or more may be perpendicular to the light beam, which detect the side scatter of the particle. Additionally, one or more detectors are situated near the light beam in order to detect light emitted from luminescent labels (e.g. fluorescent labels), which can be excited by the light beam.
  • luminescent labels e.g. fluorescent labels
  • the wavelength of the light emitted from the luminescent label must differ from the wavelength of the light beam shone onto the particle, to ensure specific detection of the label.
  • the degree of light scattering from the particle permits the size and morphology of the particle to be determined.
  • the luminescence detector permits the detection of specific components adsorbed to the particle via the emission of a certain wavelength of light from a label attached to the adsorbed component.
  • the invention provides flow cytometry for the analysis of components adsorbed to an insoluble metal salt.
  • the component In order to permit detection by the flow cytometer, the component must be labelled.
  • the adsorbed component contains an intrinsic label.
  • a detectable label is added by a binding reagent.
  • the invention provides a method for analysing a component which is adsorbed to an insoluble metal salt, comprising steps of: (i) labelling the adsorbed component with a binding reagent to produce a labelled adsorbed component; and (ii) analysing the labelled adsorbed component by flow cytometry.
  • This method is advantageous over many of the methods in the prior art because it is not necessary to desorb the component which is adsorbed to the insoluble metal salt. Instead, the adsorbed component can be analysed while it is still attached to the insoluble metal salt. In addition to the removal of the need for desorption, analysis in situ may in some circumstances also permit the determination of the activity of the adsorbed component.
  • the invention also provides a flow cytometer comprising a labelled component adsorbed to an insoluble metal salt.
  • the invention also provides a cytometer sample tube comprising a labelled component adsorbed to an insoluble metal salt.
  • the method of the invention can be illustrated using an example of a protein as the adsorbed component, and first and second antibodies as the binding reagent.
  • a blocking step which comprises incubating the adsorbed component in BSA may be performed. This ensures that any unoccupied binding sites on the insoluble metal salt are occupied, so preventing the adsorption of any binding reagents to the insoluble metal salt.
  • the adsorbed component is incubated with a first reagent, in this example an antibody, which binds to the adsorbed protein and not to any other components used in the assay.
  • a second reagent which comprises a label capable of being detected by the flow cytometer, and which binds specifically to the first reagent, for example a fluorescently labelled antibody binding to the first antibody (e.g. by binding to the Fc region of the first antibody, so that if the first antibody is a goat antibody, the second antibody should be an anti-goat antibody from another species). Wash steps are incorporated as necessary between the binding steps.
  • the method of analysing an adsorbed component by flow cytometry may comprise one or more additional steps prior to passing the adsorbed component through the flow cytometer.
  • the invention provides a method of analysing an adsorbed component comprising one or more of the steps of:
  • steps listed above is not a strict indication of the order in which they are to be performed in the method, but provides one example in which they can be combined. It is well within the capabilities of the skilled person, following the teachings herein, to generate further methods of analysis by the rearrangement and/or repetition of one or more steps. Many of the steps (e.g. sampling, adjusting the pH, diluting or concentrating etc.) may be performed more than once at different stages.
  • a range of variables can be tested to determine the optimum conditions for storage of a composition and the degree of adsorption easily and quickly determined using the method of the invention.
  • the invention provides a method of determining the stability of an adsorbed component comprising determining the degree of adsorption of a component to a metal salt by flow cytometry and repeating the flow cytometry analysis one or more times.
  • the results from the analysis of the component adsorbed to the insoluble metal salt can determine if a number of downstream steps are undertaken.
  • the properties of the analysed adsorbed component are typically compared to predetermined parameters. These parameters can be wide ranging. For instance, for a particular composition, particular sizes of insoluble metal salt particle may be preferred, particular ratios of insoluble metal salt to adsorbed component may be preferred or particular ratios of adsorbed components if the assayed composition comprises more than one, or stability for a particular period of time under specific conditions is required.
  • the particular parameters which must be met are, of course, dependent upon the insoluble metal salt, adsorbed component, buffer, and the ultimate use of the adsorbed component.
  • the method of the invention has many applications. For instance, it can form a quality control step in a manufacturing and distributing process.
  • the invention provides a method of manufacturing a composition comprising the step of analysing a labelled adsorbed component by flow cytometry and one or more of the steps of:
  • the order of steps listed above is not an indication of the order in which they are to be performed in the method of manufacture. Indeed, many of the steps (e.g. sampling, adjusting the pH, dilution or concentrating etc.) may be performed more than once at different stages in the manufacturing method.
  • the step of analysing the adsorbed component can be performed at nearly any stage in the method, and provides important information at each point. Indeed, it can be performed multiple times. For instance, a change in the buffer or the pH of the suspension to one suitable for a composition for use as a pharmaceutical may interfere with the adsorption interaction, or may cause the particles of insoluble metal salt to aggregate to a greater or lesser degree.
  • the invention provides a method of distributing an adsorbed component, or composition comprising the adsorbed component, comprising a method of flow cytometry or a method of manufacture as set out above and the step of distributing the adsorbed component or composition comprising the adsorbed component.
  • a sample of this batch will then be analysed by the method of the invention.
  • the sample is typically less than 100 ml, for example less than 50 ml, less than 40 ml, less than 30 ml, less than 20 ml, less than 10 ml, less than 5 ml, less than 4 ml, less than 3 ml, less than 2 ml, less than 1 ml, or less than 0.5 ml.
  • the sample is typically at least 100 ⁇ l, for example at least 200 ⁇ l, at least 300 ⁇ l, at least 400 ⁇ l, at least 500 ⁇ l, at least 600 ⁇ l, at least 700 ⁇ l, at least 800 ⁇ l, at least 900 ⁇ l, at least 1 ml, at least 2 ml, at least 3 ml, at least 4 ml, or at least 5 ml.
  • the batch of insoluble metal salt adsorbed component may be of a different concentration to the concentration of insoluble metal salt and/or adsorbed component that is suitable for analysis by the flow cytometry method of the invention. Therefore it may be necessary to dilute or concentrate the suspension as necessary to achieve the desired concentration of insoluble metal salt and/or adsorbed component.
  • Typical flow cytometry analysis is performed on suspensions with a particle concentration of about 10 3 -10 9 particles ml ⁇ 1 , for example 10 4 -10 8 particles ml ⁇ 1 , 10 5 -10 7 particles ml ⁇ 1 such as about 10 6 particles ml ⁇ 1 .
  • the concentration of insoluble metal salt may range from about 10 ⁇ g ml ⁇ 1 -about 100 mg ml ⁇ 1 , for example about 100 ⁇ g ml ⁇ 1 -about 10 mg ml ⁇ 1 , about 500 ⁇ g ml ⁇ 1 -about 5 mg ml ⁇ 1 , such as about 1000 to about 2000 ⁇ g ml ⁇ 1 .
  • the concentration of adsorbed component may vary, but will typically be about 1 ⁇ g ml ⁇ 1 -about 10 mg ml ⁇ 1 , for example about 10 ⁇ g ml ⁇ 1 -about 1 mg ml ⁇ 1 , about 25 ⁇ g ml ⁇ 1 -about 500 ⁇ g ml ⁇ 1 , such as about 50 ⁇ g ml ⁇ 1 to about 150 ⁇ g ml ⁇ 1
  • the adsorbed component is detected through a specific label.
  • This label may be part of the adsorbed component, for example a portion of a small molecule which contains a region of conjugated bonds, as detailed further below.
  • the label may be attached to the adsorbed component through a binding reagent. Binding reagents and labels for use in the method of the invention are discussed in more detail below.
  • the insoluble metal salt particle When the component is adsorbed to the insoluble metal salt, the insoluble metal salt particle can then be detected through the adsorbed component, either by the intrinsic label or by the one or more binding reagents used to attach a label. Thus an insoluble metal salt particle which has one or more components adsorbed to it can be distinguished from an insoluble metal salt particle which has no components attached to it. Thus the present method permits the determination of the antigen distribution on the insoluble metal salt suspension.
  • the determination of the distribution of adsorption is important to ensure that the optimum ratio of component and adjuvant has been reached, for example to ensure complete adsorption with minimum loss of excess antigen, or to ensure the maximal in vivo response.
  • the method of the invention can be used to specifically analyse a single antigen in a suspension of multiple adsorbed components.
  • the method may also be used to simultaneously analyse multiple species of adsorbed component in a suspension.
  • the suspension may contain insoluble metal salt particles with multiple different adsorbed components. This suspension may be generated by the addition of a solution containing the different species of component for adsorption to the insoluble metal salt suspension.
  • the suspension of multiple absorbed components may comprise insoluble metal salt particles each of which has only one species of component adsorbed to it. This suspension may be generated by adsorbing each component to the insoluble metal salt in isolation before combining them.
  • the method for analysing multiple adsorbed components comprises the performance of the method of the invention multiple times in parallel.
  • multiple binding reagents are added, simultaneously or serially, each binding reagent being specific in its binding for a different adsorbed component.
  • the result of the addition of the binding reagents is the linking of a different detectable label to each different adsorbed component, thus permitting the detection of each adsorbed component in isolation from the remaining components of the suspension.
  • one binding reagent may bind to all adsorbed components. This alternative would permit the detection of the total amount of adsorption by the different adsorbed component to the insoluble metal salt.
  • the multiple species of adsorbed component are adsorbed to the same metal salt (e.g. aluminium hydroxide).
  • the species are adsorbed to different metal salts, for example in a suspension comprising two adsorbed components, the first component is adsorbed to aluminium hydroxide and the second component is adsorbed to aluminium phosphate.
  • the methods of the invention typically require the use of a binding reagent which is used to label the adsorbed component.
  • the binding reagent may be a single reagent, or may comprise two or more reagents. If the binding reagent comprises more than one reagent, these reagents may be added simultaneously or sequentially.
  • the first reagent is a compound which binds to the adsorbed component, usually specifically to that adsorbed component. If the adsorbed compound is a protein or a carbohydrate, the first reagent may be an antibody which binds to the component. If the adsorbed component is a receptor, the first reagent may be a ligand which binds to that receptor (or vice versa). If the adsorbed compound is a carbohydrate, the first reagent may be a lectin.
  • the binding of a reagent to the adsorbed component may in some instances be used indicate that the component is in a biologically active from. If a particular conformation of the component is known to be necessary for the biological activity of the component, then by using an antibody which binds only to an epitope present in the active form, the active form can be specifically labelled and thus detected. Similarly, if the component is a ligand, and it can be bound by its cognate receptor, then this may be indication that the adsorbed component is in a biologically active configuration.
  • the first reagent may be linked to a label which is detectable by the flow cytometer, in which instance the first reagent will typically be the only reagent.
  • the first reagent may be linked to a label which is not detectable by the flow cytometer, i.e. a tag, for instance one partner of a typical affinity pairing (e.g. biotin and avidin), or a sequence tag such as a His 6 , myc or FLAG tag.
  • the first reagent is not labelled.
  • a second reagent is not required. If the first reagent is linked to a non-detectable label or is not labelled, then a second reagent is typically employed.
  • the second reagent usually comprises a label which is detectable by the flow cytometer.
  • the second reagent is capable of binding to the first reagent.
  • the second reagent is often an antibody with affinity for the first reagent.
  • the first reagent is an antibody
  • the second reagent is typically an antibody which binds to the first antibody (i.e. if the first reagent was a goat antibody, the second reagent should be an anti-goat antibody).
  • the first reagent comprises a label which is not detectable by the flow cytometer.
  • the second reagent can bind specifically to the label of the first reagent, for instance if the non-detectable label on the first reagent is a FLAG tag, the second reagent is ideally an anti-FLAG antibody.
  • the binding reagent is an antibody it may be a polyclonal antibody or a monoclonal antibody. It is preferred to use a monoclonal antibody where binding to a specific epitope is desired, for instance in the situation where specifically an active form of adsorbed component is being labelled.
  • Antibodies of the invention can be of any isotype (e.g. IgA, IgG, IgM i.e. an ⁇ , ⁇ or ⁇ heavy chain) and may have a ⁇ or a ⁇ light chain.
  • the antibody may be derived from a variety sources, for example human, cow, rat, mouse, pig, goat, rabbit, camel, sheep, guinea pig, snake, frog, llama, carp, shark, dog, cat, duck ostrich or chicken.
  • binding reagent comprising more than one reagent will be composed of two reagents, there is no upper limit to the number of reagents. All that is required is that each reagent of the binding reagent should bind to the preceding reagent, and ultimately introduce a label which is specifically bound to the adsorbed component.
  • the binding reagent may comprise one, two, three, four, five, six, seven, eight, nine, ten or more than ten reagents.
  • the adsorbed component is not intrinsically fluorescent (i.e. it does not autofluoresce) then, as detailed previously, it is necessary to use one or more binding reagents which comprise a label which can be detected by the flow cytometer. Typically this will be a luminescent label, for example a fluorescent label.
  • a luminescent label for example a fluorescent label.
  • the intrinsic fluorescence of the components can be simply determined by passing the assay components through the flow cytometer without the detectable label, as described herein.
  • Labels should be selected with absorption and emission spectra which do not interfere, or do not interfere to a significant extent, with those of the assay components.
  • the spectra do not interfere to a significant degree if the labelled adsorbed component can be specifically and sensitively detected when it passes through the flow cytometer.
  • adsorbed compounds may intrinsically fluoresce, a phenomenon also termed autofluorescence.
  • the use of one or more binding reagents to label the adsorbed component is not required to permit the detection of the adsorbed complex by flow cytometry. Instead, flow cytometry analysis can be performed immediately following adsorption.
  • one or more wash steps to remove unbound adsorbed component from the insoluble metal salt particles may be employed.
  • Intrinsically fluorescent adsorbed components typically contain conjugated systems, i.e. a system of connected p-orbitals in a series of alternating single and double bonds, which allow delocalisation of pi electrons.
  • the conjugated system may be aromatic, non-aromatic or anti-aromatic.
  • An exemplary class of autofluorescent molecules comprises a benzonaphthyridine scaffold, for example SMIPs which are analogs of Compound A.
  • SMIPs which are analogs of Compound A.
  • a number of analogs of Compound A are displayed in Table 2, including compounds B to H.
  • Any of the general and specific compounds in references 6 can be analysed using the invention, as can other autofluorescent molecules (in particular SMIPs) which comprise a phosphonate group (or a phosphinate, a phosphonite, a phosphinite, or a phosphate group) and which can adsorb to insoluble metal salts.
  • the autofluorescent adsorbed component may be a protein. Fluorescence by a protein may be the result of intrinsic fluorescence of tryptophan residues in that protein, though a lesser contribution to fluorescence may be made by tyrosine and phenylalanine residues.
  • the three residues have distinct absorption and emission maxima, which are typically as follows: tryptophan absorbs at 280 nm and fluoresces at 348 nm, tyrosine absorbs at 274 nm and fluoresces at 303 nm and phenylalanine absorbs at 257 nm and fluoresces at 282 nm.
  • the exact absorption and fluorescence wavelengths of the residue depend on the local chemical environment of the residue.
  • Tryptophan residues which are in hydrophobic regions of a proteins, for instance the core can have spectra which are shifted by 10 to 20 nm compared to a tryptophan in the hydrophilic regions, e.g. the surface, of the protein.
  • the fluorescence of that cofactor may be used as a label to detect the component.
  • NADH and/or NADPH are cofactors for a number of proteins, and have approximate absorption and fluorescence maxima at 340 nm and 460 nm respectively.
  • Riboflavin, FMN and FAD absorb at approximately 450 nm and fluoresce at approximately 525 nm.
  • Other cofactors are based on a porphyrin ring. Proteins comprising a porphyrin ring include heme containing proteins and chlorophyll containing proteins.
  • GFP green fluorescent protein
  • GFP green fluorescent protein
  • its derivatives comprise an imidazolin-5-one heterocyclic ring fluorophore formed from the tripeptide Thr-Tyr-Gly present in the primary sequence of the protein.
  • the invention encompasses methods in which there are multiple adsorbed components, at least one of which is autofluorescent and at least one of which is labeled using a binding reagent e.g. an embodiment in which both an antigen and a compound of Table 2 are adsorbed to a metal salt.
  • a further step to block the free sites prior to the addition of a binding reagent may be performed.
  • blocking is meant the addition of a further reagent which is capable of adsorption to the insoluble metal salt, but which differs from the adsorbed component and which is not recognised by a binding reagent.
  • a typical reagents used to block binding sites on the insoluble metal salt includes one or more of BSA, newborn calf serum, casein, casein digest, milk powder (e.g. skimmed milk powder), chick albumin, rabbit serum, horse serum, goat serum, mouse serum, human serum, rat serum, pig serum, Block Ace (Serotec), E. coli extract, pig skin gelatin, fish skin gelatin, steelhead salmon serum, Protein-Free Blocking Buffer (Pierce), salmon sperm DNA and randomly sheared genomic DNA.
  • BSA newborn calf serum
  • casein casein digest
  • milk powder e.g. skimmed milk powder
  • chick albumin rabbit serum, horse serum, goat serum, mouse serum, human serum, rat serum, pig serum, Block Ace (Serotec), E. coli extract, pig skin gelatin, fish skin gelatin, steelhead salmon serum, Protein-Free Blocking Buffer (Pierce), salmon sperm DNA and randomly sheared genomic DNA.
  • a wash step comprises centrifuging the insoluble metal salt particles to form a pellet, aspirating the supernatant and replacing it with a fresh buffer solution.
  • the suspension is then passed through the flow cytometer which is able to detect the size of the particle (thus providing information on the number of insoluble metal salt particles in the desired size range and also excluding any aggregates of binding reagent from analysis) and also any luminescence from the label bound to the adsorbed component (which permits differentiation between insoluble metal salt particles which have component adsorbed to them, and those which do not, and also the degree of adsorption).
  • the proportion of the particles in the suspension which are of appropriate size and which also fluoresce appropriately (indicating the presence of the adsorbed component) can be determined. This information can then be used to determine whether or not the batch of material which has been assayed is suitable for use in downstream processes.
  • components can adsorb to insoluble metal salts, thereby forming an adsorbed complex.
  • insoluble metal salts e.g. calcium phosphate
  • aluminium salts have a long history of use in vaccines.
  • Aluminium salts which include hydroxide ions are the preferred insoluble metal salts for use with the present invention.
  • Useful aluminium salts include, but are not limited to, aluminium hydroxide, aluminium oxyhydroxide, and aluminium hydroxyphosphates (including aluminium hydroxyphosphate sulfate). Such salts are described e.g. in chapters 8 & 9 of reference 7.
  • Preferred salts for adsorption of components are aluminium oxyhydroxides and/or aluminium hydroxyphosphate. These have surface hydroxyl moieties which can readily undergo ligand exchange with phosphorus-containing groups (e.g. phosphates, phosphonates) to provide stable adsorption.
  • phosphorus-containing groups e.g. phosphates, phosphonates
  • aluminium hydroxide typically aluminium oxyhydroxide salts, which are usually at least partially crystalline.
  • Aluminium oxyhydroxide which can be represented by the formula AlO(OH)
  • IR infrared
  • adsorption band at 1070 cm ⁇ 1 and a strong shoulder at 3090-3100 cm ⁇ 1 (chapter 9 of ref. 7).
  • the degree of crystallinity of an aluminium hydroxide adjuvant is reflected by the width of the diffraction band at half height (WHH), with poorly-crystalline particles showing greater line broadening due to smaller crystallite sizes.
  • aluminium hydroxide adjuvants The surface area increases as WHH increases, and adjuvants with higher WHH values have been seen to have greater capacity for antigen adsorption.
  • a fibrous morphology e.g. as seen in transmission electron micrographs
  • the pI of aluminium hydroxide adjuvants is typically about 11 i.e. the adjuvant itself has a positive surface charge at physiological pH.
  • Adsorptive capacities of between 1.8-2.6 mg protein per mg Al +++ at pH 7.4 have been reported for aluminium hydroxide adjuvants.
  • the adjuvants commonly known as “aluminium phosphate” are typically aluminium hydroxyphosphates, often also containing a small amount of sulfate (i.e. aluminium hydroxyphosphate sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt. Hydroxyphosphates generally have a PO 4 /Al molar ratio between 0.3 and 1.2. Hydroxyphosphates can be distinguished from strict AlPO 4 by the presence of hydroxyl groups. For example, an IR spectrum band at 3164 cm ⁇ 1 (e.g. when heated to 200° C.) indicates the presence of structural hydroxyls (chapter 9 of reference 7).
  • the PO 4 /Al 3+ molar ratio of an aluminium phosphate adjuvant will generally be between 0.3 and 1.2, preferably between 0.8 and 1.2, and more preferably 0.95 ⁇ 0.1.
  • the aluminium phosphate will generally be amorphous, particularly for hydroxyphosphate salts.
  • a typical adjuvant is amorphous aluminium hydroxyphosphate with PO 4 /Al molar ratio between 0.84 and 0.92, included at 0.6 mg Al 3+ /ml.
  • the aluminium phosphate will generally be particulate (e.g. plate-like morphology as seen in transmission electron micrographs). Typical diameters of the particles are in the range 0.5-20 ⁇ m (e.g. about 5-10 ⁇ m) after any antigen adsorption.
  • Adsorptive capacities of between 0.7-1.5 mg protein per mg Al +++ at pH 7.4 have been reported for aluminium phosphate adjuvants.
  • a composition including a component adsorbed to an insoluble metal salt can also include a buffer (e.g. a phosphate or a histidine or a Tris buffer).
  • a buffer e.g. a phosphate or a histidine or a Tris buffer.
  • compositions containing adsorbed components will generally be suspensions having a cloudy appearance. This can mask contaminating bacterial growth and so the method of manufacturing a composition from a batch an adsorbed component (which has been assayed by flow cytometry) may include the step of adding a preservative such as thiomersal or 2-phenoxyethanol. It is preferred that a composition should be substantially free from (e.g. ⁇ 10 ⁇ g/ml) mercurial material e.g. thiomersal-free. Methods of manufacturing a composition containing no mercury are more preferred. Thus a method of the invention may comprise the step of removing mercurial material from a suspension of adsorbed component.
  • a composition can include a mixture of both an aluminium oxyhydroxide and an aluminium hydroxyphosphate, and adsorbed components may be adsorbed to one or both of these salts.
  • the concentration of Al +++ in a composition for administration to a patient is preferably less than 10 mg/ml e.g. ⁇ 5 mg/ml, ⁇ 4 mg/ml, ⁇ 3 mg/ml, ⁇ 2 mg/ml, ⁇ 1 mg/ml, etc.
  • a preferred range is between 0.3 and 1 mg/ml.
  • a maximum of ⁇ 0.85 mg/dose is preferred.
  • the concentration of Al +++ in the pharmaceutical composition may differ from the concentration in the suspension analysed by the flow cytometry method of the invention.
  • the invention can be used with a wide range of adsorbed components which can be used for treating or protecting against a wide range of diseases.
  • the adsorbed component may elicit an immune response that protects against a viral disease (e.g. due to an enveloped or non-enveloped virus), a bacterial disease (e.g. due to a Gram negative or a Gram positive bacterium), a fungal disease, a parasitic disease, an auto-immune disease, or any other disease.
  • the adsorbed component may also be useful in immunotherapy e.g. for treating a tumour/cancer, Alzheimer's disease, or an addiction.
  • the adsorbed component may take various forms e.g. a whole organism, an outer-membrane vesicle, a polypeptide, a saccharide, a liposaccharide, a conjugate (e.g. of a carrier and a hapten, or of a carrier and a saccharide or liposaccharide), etc.
  • the adsorbed component is a polypeptide, it will typically be a surface polypeptide e.g. an adhesin, a hemagglutinin, an envelope glycoprotein, a spike glycoprotein, etc.
  • the adsorbed component may elicit an immune response against an influenza virus, including influenza A and B viruses.
  • influenza virus immunogen are currently available, typically based either on live virus or on inactivated virus.
  • Inactivated vaccines may be based on whole virions, split virions, or on purified surface antigens.
  • Influenza antigens can also be presented in the form of virosomes.
  • Hemagglutinin is the main adsorbed component in current inactivated vaccines, and vaccine doses are standardised by reference to HA levels, typically measured by SRID.
  • Existing vaccines typically contain about 15 ⁇ g of HA per strain, although lower doses can be used e.g. for children, or in pandemic situations, or when using an adjuvant.
  • compositions may include between 0.1 and 150 ⁇ g of HA per influenza strain, preferably between 0.1 and 50 ⁇ g e.g. 0.1-20 ⁇ g, 0.1-15 ⁇ g, 0.1-10 ⁇ g, 0.1-7.5 ⁇ g, 0.5-5 ⁇ g, etc.
  • Particular doses include e.g. about 45, about 30, about 15, about 10, about 7.5, about 5, about 3.8, about 3.75, about 1.9, about 1.5, etc. per strain.
  • HA mass for each strain included in the vaccine e.g. such that the HA mass for each strain is within 10% of the mean HA mass per strain, and preferably within 5% of the mean.
  • dosing is measured by median tissue culture infectious dose (TCID 50 ) rather than HA content, and a TCID 50 of between 10 6 and 10 8 (preferably between 10 6.5 -10 7.5 ) per strain is typical.
  • TCID 50 median tissue culture infectious dose
  • cell lines that support influenza virus replication may be used.
  • the cell line will typically be of mammalian origin e.g. MDCK.
  • Influenza A virus adsorbed components may be from any suitable HA subtype strain e.g. H1, H3, H5, H7, H9 etc., such as a H1N1, H3N2 and/or H5N1 strain.
  • the adsorbed component may elicit an immune response against a Candida fungus such as C. albicans .
  • the adsorbed component may be a ⁇ -glucan, which may be conjugated to a carrier protein.
  • the glucan may include ⁇ -1,3 and/or ⁇ -1,6 linkages.
  • Suitable adsorbed components include those disclosed in references 10 & 11.
  • the adsorbed component may elicit an immune response against a Streptococcus bacterium, including S. agalactiae, S. pneumoniae and S. pyogenes .
  • the adsorbed component may be a capsular saccharide, which may be conjugated to a carrier protein.
  • the saccharide may be from one or more of serotypes Ia, Ib, II, III, and/or V.
  • S. pneumoniae the saccharide may be from one or more of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and/or 23F.
  • polypeptide adsorbed components may be used to elicit a protective anti-streptococcal immune response e.g. comprising RrgB, as disclosed in reference 12.
  • the adsorbed component may elicit an immune response against a Staphylococcus bacterium, including S. aureus or S. epidermidis .
  • the immunogen may comprise an IsdA antigen, an IsdB antigen, a ClfA antigen, a ClfB antigen, a SdrD antigen, a Spa antigen, an EsxA antigen, an EsxB antigen, a Sta006 antigen, a hemolysin, and/or a Sta011 antigen.
  • Suitable S. aureus immunogens and their combinations are disclosed in reference 13.
  • the adsorbed component may elicit an immune response against a meningococcal bacterium ( Neisseria meningitidis ).
  • the adsorbed component may be a capsular saccharide, which may be conjugated to a carrier protein.
  • Capsular saccharides are particularly useful for protecting against meningococcal serogroups A, C, W135 and/or Y.
  • polypeptide adsorbed components and/or outer membrane vesicles may be used to elicit a protective anti-meningococcal immune response, particularly for use against serogroup B e.g. as disclosed in reference 14.
  • the adsorbed component may elicit an immune response against a hepatitis virus, such as a hepatitis A virus, a hepatitis B virus, a hepatitis C virus and/or a hepatitis E virus.
  • a hepatitis virus such as a hepatitis A virus, a hepatitis B virus, a hepatitis C virus and/or a hepatitis E virus.
  • the adsorbed component may be hepatitis B virus surface antigen (HBsAg).
  • the adsorbed component may elicit an immune response against a respiratory syncytial virus.
  • Adsorbed components may be from a group A RSV and/or a group B RSV.
  • Suitable immunogens may comprise the F and/or G glycoproteins or fragments thereof e.g. as disclosed in references 15 & 16.
  • the adsorbed component may elicit an immune response against a Chlamydia bacterium, including C. trachomatis and C. pneumoniae .
  • Suitable adsorbed components include those disclosed in references 17-23.
  • the adsorbed component may elicit an immune response against an Escherichia coli bacterium, including extraintestinal pathogenic strains.
  • Suitable adsorbed components include those disclosed in references 24-26.
  • the adsorbed component may elicit an immune response against a coronavirus, such as the human SARS coronavirus.
  • Suitable adsorbed components may comprise the spike glycoprotein.
  • the adsorbed component may elicit an immune response against a Helicobacter pylori bacterium.
  • Suitable adsorbed components include CagA [27-30], VacA [31,32], and/or NAP [33-35].
  • the adsorbed component may elicit an immune response against rabies virus.
  • a suitable adsorbed component is an inactivated rabies virus [36, RabAvertTM].
  • the adsorbed component may elicit an immune response against a human papillomavirus.
  • Useful immunogens are L1 capsid proteins, which can assemble to form structures known as virus-like particles (VLPs).
  • the VLPs can be produced by recombinant expression of L1 in yeast cells (e.g. in S. cerevisiae ) or in insect cells (e.g. in Spodoptera cells, such as S. frugiperda , or in Drosophila cells).
  • yeast cells plasmid vectors can carry the L1 gene(s); for insect cells, baculovirus vectors can carry the L1 gene(s).
  • the composition includes L1 VLPs from both HPV-16 and HPV-18 strains. This bivalent combination has been shown to be highly effective [37]. In addition to HPV-16 and HPV-18 strains, it is also possible to include L1 VLPs from HPV-6 and HPV-11 strains.
  • the adsorbed component may elicit an immune response against a tumour antigen, such as MAGE-1, MAGE-2, MAGE-3 (MAGE-A3), MART-1/Melan A, tyrosinase, gp100, TRP-2, etc.
  • a tumour antigen such as MAGE-1, MAGE-2, MAGE-3 (MAGE-A3), MART-1/Melan A, tyrosinase, gp100, TRP-2, etc.
  • the adsorbed component may elicit an immunotherapeutic response against lung cancer, melanoma, breast cancer, prostate cancer, etc.
  • the adsorbed component may elicit an immune response against a hapten conjugated to a carrier protein, where the hapten is a drug of abuse [38].
  • hapten is a drug of abuse [38].
  • examples include, but are not limited to, opiates, marijuana, amphetamines, cocaine, barbituates, glutethimide, methyprylon, chloral hydrate, methaqualone, benzodiazepines, LSD, nicotine, anticholinergic drugs, antipsychotic drugs, tryptamine, other psychomimetic drugs, sedatives, phencyclidine, psilocybine, volatile nitrite, and other drugs inducing physical and/or psychological dependence.
  • compositions for Immunisation against Neisseria meningitidis are provided.
  • the flow cytometry method of the invention is particularly useful for assaying adsorbed components in immunogenic compositions for immunising against meningococcus e.g. against serogroup B.
  • Preferred immunogenic compositions prepared by the method of manufacturing disclosed herein comprise: (i) an aluminium hydroxide adjuvant; (ii) compound 1, 2 or 5 herein; (iii) a first polypeptide comprising SEQ ID NO: 1; (iv) a second polypeptide comprising SEQ ID NO: 2; and (v) a third polypeptide comprising SEQ ID NO: 3, 4 or 5; wherein compound of (ii) is adsorbed to the aluminium hydroxide.
  • polypeptides used with the invention may, compared to the SEQ ID NOs herein, include one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, etc.) amino acid substitutions, such as conservative substitutions (i.e. substitutions of one amino acid with another which has a related side chain).
  • Genetically encoded amino acids are generally divided into four families: (1) acidic i.e. aspartate, glutamate; (2) basic i.e. lysine, arginine, histidine; (3) non-polar i.e. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar i.e.
  • polypeptides may also include one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, etc.) single amino acid deletions relative to the SEQ ID NO sequences.
  • polypeptides may also include one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, etc.) insertions (e.g. each of 1, 2, 3, 4 or 5 amino acids) relative to the SEQ ID NO sequences.
  • the composition produced by the method of manufacturing may include 5-100 ⁇ g of each polypeptide.
  • the composition ideally does not include any bacterial outer membrane vesicles.
  • the composition produced by the method of manufacturing may include from 5-100 ⁇ g of compound 1, 2 or 5.
  • it may include from 5-100 ⁇ g of compound 2, or it may include from 5-100 ⁇ g of compound 5.
  • the composition may include a histidine buffer e.g. a 10 mM histidine buffer. It may include sucrose and/or sodium chloride. It may be administered in a dosage volume of 0.5 ml e.g. for intramuscular injection.
  • a histidine buffer e.g. a 10 mM histidine buffer. It may include sucrose and/or sodium chloride. It may be administered in a dosage volume of 0.5 ml e.g. for intramuscular injection.
  • the adsorbed component for analysis by the method of the invention may be an agonist of a receptor.
  • the adsorbed agonist may be the naturally occurring cognate ligand of the receptor.
  • the adsorbed agonist may be a non-naturally occurring ligand of the receptor.
  • the adsorbed agonist may be a peptide mimetic of the receptor or a small molecule capable of binding to the receptor.
  • An example of a small molecule capable of binding to the receptor is a SMIP (small molecule immunopotentiator).
  • the adsorbed component may be a TLR agonist which comprises an adsorptive moiety and a TLR agonist moiety.
  • the adsorptive moiety confers the ability to adsorb to an insoluble metal salt (see above), whereas the TLR agonist moiety confers the ability to agonise a Toll-like receptor.
  • a TLR agonist assayed by the method of the invention would thus function as a TLR agonist even without its adsorptive moiety.
  • TLR agonists can activate any of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 or TLR11.
  • the compound is preferably an agonist of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10 or TLR11.
  • a more preferred subgroup is TLR2, TLR7 and TLR8.
  • Another preferred subgroup is TLR2 and TLR7.
  • a TLR agonist is an agonist of a human TLR.
  • the method of the invention can be used to analyse components adsorbed to insoluble metal salts from a batch of adsorbed component which is then used in the manufacture of pharmaceutical compositions and products.
  • the assayed batch of adsorbed component can be formulated in numerous ways, and the formulation can comprise many further components.
  • a pharmaceutical composition comprising the adsorbed component may be generated by the addition of one or more pharmaceutically acceptable excipients. A thorough discussion of such components is available in reference 40.
  • compositions comprising the adsorbed component are preferably in aqueous form, particularly at the point of administration, but they can also be presented in non-aqueous liquid forms or in dried forms e.g. as gelatin capsules, or as lyophilisates, etc., following analysis by a method of the present invention.
  • a method of the invention may comprise the step of lyophilising a suspension of an adsorbed component.
  • compositions comprising the adsorbed component may include one or more preservatives, such as thiomersal or 2-phenoxyethanol.
  • preservatives such as thiomersal or 2-phenoxyethanol.
  • Mercury-free compositions are preferred, and preservative-free vaccines can be prepared.
  • a method of the invention may comprise the step of adding a preservative.
  • compositions comprising the adsorbed component can include a physiological salt, such as a sodium salt e.g. to control tonicity.
  • a physiological salt such as a sodium salt e.g. to control tonicity.
  • Sodium chloride (NaCl) is typical, which may be present at between 1 and 20 mg/ml e.g. 10 ⁇ 2 mg/ml or 9 mg/ml.
  • Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, etc.
  • a method of the invention may comprise the step of adding a physiological salt.
  • compositions comprising the adsorbed component can have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, e.g. between 240-360 mOsm/kg, or between 290-310 mOsm/kg.
  • a method of the invention may comprise the step of adjusting the osmolality of the suspension of adsorbed component to between 200 mOsm/kg and 400 mOsm/kg, e.g. between 240-360 mOsm/kg, or between 290-310 mOsm/kg.
  • Pharmaceutical compositions comprising the adsorbed component may include compounds in plain water (e.g. w.f.i.) but will usually include one or more buffers.
  • Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (particularly with an aluminium hydroxide adjuvant); or a citrate buffer.
  • Buffer salts will typically be included in the 5-20 mM range.
  • a method of the invention may comprise the step of adding or exchanging the buffer in a suspension of adsorbed component, for example to a phosphate buffer, a Tris buffer, a borate buffer, a succinate buffer or a histidine buffer.
  • compositions comprising the adsorbed component typically have a pH between 5.0 and 9.5 e.g. between 6.0 and 8.0.
  • a method of the invention may comprise the step of adjusting the pH of a suspension of adsorbed component, optionally to between 5.0 and 9.5 e.g. between 6.0 and 8.0.
  • compositions are preferably sterile.
  • a method of the invention may comprise the step of sterilising a suspension of adsorbed component.
  • compositions preferably non-pyrogenic e.g. containing ⁇ 1 EU (endotoxin unit, a standard measure) per dose, and preferably ⁇ 0.1 EU per dose.
  • a method of the invention may comprise the step of removing endotoxin from a suspension of adsorbed component.
  • compositions are preferably gluten free.
  • a method of the invention may comprise the step of removing gluten from a suspension of adsorbed component.
  • compositions prepared by the method of manufacture of the invention are suitable for administration to animal (and, in particular, human) patients, and thus include both human and veterinary uses. They may be used in a method of raising an immune response in a patient, comprising the step of administering the composition to the patient.
  • compositions may be prepared in unit dose form.
  • a unit dose may have a volume of between 0.1-1.0 ml e.g. about 0.5 ml.
  • a method of the invention may comprise the step of preparing a unit dose.
  • compositions assayed by the methods of the invention may be prepared in various forms.
  • the compositions may be prepared as injectables, either as liquid solutions or suspensions.
  • Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared (e.g. a lyophilised composition or a spray-freeze dried composition).
  • the composition may be prepared for topical administration e.g. as an ointment, cream or powder.
  • the composition may be prepared for oral administration e.g. as a tablet or capsule, as a spray, or as a syrup (optionally flavoured).
  • the composition may be prepared for pulmonary administration e.g. by an inhaler, using a fine powder or a spray.
  • the composition may be prepared as a suppository or pessary.
  • the composition may be prepared for nasal, aural or ocular administration e.g. as a spray or drops.
  • the composition may be in kit form, designed such that a combined composition is reconstituted just prior to administration to a patient.
  • kits may comprise one or more antigens in liquid form and one or more lyophilised antigens.
  • injectables for intramuscular administration are typical.
  • a method of the invention may comprise the step of preparing an injectable.
  • Compositions comprise an effective amount of one or more adjuvanted components i.e. an amount which, when administered to an individual, either in a single dose or as part of a series, is effective for enhancing the immune response.
  • This amount can vary depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non-human primate, primate, etc.), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors.
  • the amount will fall in a relatively broad range that can be determined through routine trials.
  • An amount of between 1-1000 m/dose can be used e.g. from 10-100 ⁇ g per dose.
  • a method of the invention may comprise the step of diluting or concentrating the adsorbed component to achieve a concentration suitable for preparing a unit dose.
  • composition “comprising” encompasses “including” as well as “consisting” e.g. a composition “comprising” X may consist exclusively of X or may include something additional e.g. X+Y.
  • a process comprising a step of mixing two or more components does not require any specific order of mixing.
  • components can be mixed in any order. Where there are three components then two components can be combined with each other, and then the combination may be combined with the third component, etc.
  • animal (and particularly bovine) materials are used in the culture of cells, they should be obtained from sources that are free from transmissible spongiform encaphalopathies (TSEs), and in particular free from bovine spongiform encephalopathy (BSE). Overall, it is preferred to culture cells in the total absence of animal-derived materials.
  • TSEs transmissible spongiform encaphalopathies
  • BSE bovine spongiform encephalopathy
  • a compound is administered to the body as part of a composition then that compound may alternatively be replaced by a suitable prodrug.
  • antibody includes any of the various natural and artificial antibodies and antibody-derived proteins which are available, and their derivatives, e.g. including without limitation polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, single-domain antibodies, whole antibodies, antibody fragments such as F(ab′)2 and F(ab) fragments, Fv fragments (non-covalent heterodimers), single-chain antibodies such as single chain Fv molecules (scFv), minibodies, oligobodies, dimeric or trimeric antibody fragments or constructs, etc.
  • the term “antibody” does not imply any particular origin, and includes antibodies obtained through non-conventional processes, such as phage display.
  • Antibodies of the invention can be of any isotype (e.g. IgA, IgG, IgM i.e. an ⁇ , ⁇ or ⁇ heavy chain) and may have a ⁇ or a ⁇ light chain.
  • FIG. 1 is an image of an SDS-PAGE gel displaying the adsorption capacity of aluminium hydroxide for the antigen NadA. Odd numbered lanes are supernatant treated with deoxycholic acid sodium salt (DOC) and trichloroacetic acid (TCA) of aluminium hydroxide adsorbed samples at 50, 100, 200, 400, 800 and 1600 ⁇ g ml ⁇ 1 of NadA. Even lanes are aluminium hydroxide pellet desorbed samples from formulation with: 50, 100, 200, 400, 800 and 1600 ⁇ g ml ⁇ 1 of NadA. Each sample contained 3000 ⁇ g ml ⁇ 1 aluminium hydroxide.
  • DOC deoxycholic acid sodium salt
  • TCA trichloroacetic acid
  • FIGS. 2 a -2 g are a series of histograms showing an increase in fluorescence detected with increasing concentrations of NadA ( FIG. 2 a ) 0 ⁇ g m ⁇ 1 ( FIG. 2 b ) 50 ⁇ g ml ⁇ 1 ( FIG. 2 c ) 100 ⁇ g ml ⁇ 1 ( FIG. 2 d ) 200 ⁇ g ml ⁇ 1 ( FIG. 2 e ) 400 ⁇ g ml ⁇ 1 ( FIG. 2 f ) 800 ⁇ g ml ⁇ 1 and ( FIG. 2 g ) 1600 ⁇ g ml ⁇ 1 .
  • the left hand peak in each image represents aluminium hydroxide particles without adsorbed component. With increasing concentration, a larger proportion of particles are seen to shift to the right, indicating an elevated level of fluorescence from a label specifically attached to NadA.
  • FIGS. 3 a -3 d are a series of histograms showing the results of the tests for autoflorescence of the assay components. The histograms represent the event counts versus the fluorescence measured for the APC-A channel 660/20.
  • FIG. 3 a Analysis of aluminium hydroxide by flow cytometry identifies 99% of the aggregates as having fluorescence intensity less than 1000.
  • FIGS. 3 b , 3 c , 3 d Similar analyses of aluminium hydroxide together with assay components (NadA (b), NadA+BSA ( FIG. 3 c ), and NadA, BSA and anti-NadA rabbit antibody ( FIG. 3 d )) indicated no inherent fluorescence over the background level for the antigen NadA, the blocking agent (BSA) or by the primary antibody.
  • BSA blocking agent
  • FIGS. 4 a -4 c are a series of histograms showing the specificity of antibody binding to NadA adsorbed to aluminium hydroxide. The histograms represent the event counts in percentage (%) versus the relative fluorescence intensity measured for the APC-Alexa 647 at channel 660/20 for various sample controls.
  • FIG. 4 a Non-specific binding was determined by performing the flow cytometry assay in absence of antigen with primary antibody diluted 1:1000 and 1:1000 or containing 100 ⁇ g ml ⁇ 1 NadA but using irrelevant primary antibody.
  • FIG. 4 a Non-specific binding was determined by performing the flow cytometry assay in absence of antigen with primary antibody diluted 1:1000 and 1:1000 or containing 100 ⁇ g ml ⁇ 1 NadA but using irrelevant primary antibody.
  • FIG. 5 is a representation of scatter plots for all standard formulations (0-300 ⁇ g ml ⁇ 1 ).
  • the gated dots appeared as a single uniform population of particles with increased concentration of adsorbed NadA having no impact on forward and side scatter measurements.
  • FIGS. 6 a -6 g are a series of scatter plots forming an analysis of the antigen distribution of NadA on aluminium hydroxide aggregates using side scattering and relative fluorescence intensity (RFI).
  • the percentage of florescent particles increases with the concentration of NadA (0, 9.375, 18.75, 37.5, 75, 150, 300 ⁇ gml ⁇ 1 ).
  • FIG. 6 a shows the percentage of fluorescent particles at a concentration of 0 ⁇ g/ml ⁇ 1 NadA.
  • FIG. 6 b shows the percentage of fluorescent particles at a concentration of 9.375 ⁇ g/ml ⁇ 1 NadA.
  • FIG. 6 c shows the percentage of fluorescent particles at a concentration of 18.75 ⁇ g/ml ⁇ 1 NadA.
  • FIG. 6 d shows the percentage of fluorescent particles at a concentration of 37.5 ⁇ g/ml ⁇ 1 NadA.
  • FIG. 6 e shows the percentage of fluorescent particles at a concentration of 75 ⁇ g/ml ⁇ 1 NadA.
  • FIG. 6 f shows the percentage of fluorescent particles at a concentration of 150 ⁇ g/ml ⁇ 1 NadA.
  • FIG. 6 g shows the percentage of fluorescent particles at a concentration of 300 ⁇ g/ml ⁇ 1 NadA.
  • the y axis displays the percentage of particles with relative fluorescence intensity>1000.
  • Each value represents the mean and standard deviations of triplicate samples performed on three independent experiments. Results showed the detection of the MenB antigen NadA in the range of 3.12-100 ⁇ g/dose (6.24-200 ⁇ g ml ⁇ 1 ).
  • FIG. 8 is a graph showing the excitation profile of a number of SMIPs.
  • FIGS. 9 a -9 d are a series of scatter plots providing a morphological analysis of aluminium hydroxide-Compound C formulation and controls based on forward and side scatter parameters (FSC and SSC).
  • FIG. 9 a Aluminium hydroxide
  • FIG. 9 b Compound C
  • FIG. 9 c Filtered compound C
  • FIG. 9 d Compound C adsorbed to aluminium hydroxide.
  • FIGS. 10 a -10 c are a series of scatter plots providing a morphological analysis of aluminium hydroxide +Compound A formulation and relative controls based on forward and side scatter parameters (FSC and SSC).
  • FIG. 10 a Aluminium hydroxide
  • FIG. 10 b Compound A
  • FIG. 10 c Compound A with aluminium hydroxide.
  • FIGS. 11 a -11 n show a series of histograms showing the shift of the positive fluorescence peak detected with labeled secondary antibody 961c specific.
  • the shift to the right is directly proportional to amount of 961c adsorbed onto aluminum hydroxide particles adsorbed with 961c only ( FIGS. 11 a -11 g ), and when this component was adsorbed as part of a 3-component combination ( FIGS. 11 h -11 n ).
  • FIGS. 11 a , 11 h 0 ⁇ g ml ⁇ 1
  • FIGS. 11 b , 11 i 50 ⁇ g ml ⁇ 1
  • FIGS. 11 c , 11 j 100 ⁇ g ml ⁇ 1 , ( FIGS. 11 d , 11 k ) 150 ⁇ g ml ⁇ 1 , ( FIGS. 11 e , 11 ⁇ 1 ) 200 ⁇ g ml ⁇ 1 , ( FIGS. 11 f , 11 m ) 250 ⁇ g ml ⁇ 1 , ( FIGS. 11 g ,) 400 ⁇ g ml ⁇ 1 , and ( FIGS. 11 n ) 300 ⁇ g ml ⁇ 1 .
  • FIGS. 12 a -12 c are a series of histograms showing fluorescence traces for aluminium hydroxide formulations for ( FIG. 12 a ) Compound B and ( FIG. 12 b ) Compound C.
  • the histograms show increased fluorescence intensity of SMIP-aluminium hydroxide particles (both in the presence and absence of an antigen) with respect to negative controls. This increase is irrespective of whether or not the aluminium hydroxide also has a protein component adsorbed to it.
  • Aluminium hydroxide mixed with Compound A ( FIG. 12 c ), on the contrary, does not show fluorescence as Compound A does not adsorb on aluminium hydroxide particles.
  • FIG. 13 a is a histogram which shows that prior to adsorption and following desorption of SMIP Compound B, aluminium hydroxide particles do not fluoresce in the same manner as when Compound B is adsorbed
  • FIG. 13 b is a histogram which shows that prior to adsorption and following desorption of SMIP Compound C, aluminium hydroxide particles do not fluoresce in the same manner as when Compound C is adsorbed.
  • FIG. 14 is a graph showing the excitation profile of two further SMIPs.
  • FIGS. 15 a -15 d are a series of scatter plots providing a morphological analysis of aluminium hydroxide-Compound E formulation and controls based on forward and side scatter parameters (FSC and SSC) and a series of histograms showing fluorescence traces for aluminium hydroxide formulations for Compound E.
  • FIG. 15 a PBS/PBS
  • FIG. 15 b 153/153
  • FIG. 15 c PBS/Alum
  • FIG. 15 d Alum LHD153/Alum LHD153.
  • GMP Clinical grade material
  • MenB Neisseria meningitidis serogroup B
  • Anti-NadA polyclonal rabbit antibody was used as primary antibody at 1:500, dilution in 10 mM histidine buffer, pH 6.5.
  • Alexa Fluor 647 F(ab′)2 fragment of goat anti-rabbit antibody was purchased from Molecular Probes and used at 1:800 dilution in 1 ⁇ PBS. This antibody was utilized as the final step of the assay.
  • a set of standard suspensions containing the antigen NadA at 300 ⁇ g ml ⁇ 1 and five serial two-fold dilutions was prepared by serially diluting a stock suspension sample the day before the assay.
  • the stock suspension was prepared by mixing 1500 ⁇ g of aluminium hydroxide per 150 ⁇ g of NadA in 10 mM histidine buffer (pH 6.5). The final osmolarity of the formulation was adjusted to 300 mOsm/L using a 2M NaCl solution. The concentration of aluminium hydroxide in the stock solution was 3000 ⁇ g ml ⁇ 1 and the concentration of NadA was 300 ⁇ g ml ⁇ 1 . The antigen was adsorbed by stirring the stock suspension for at least two hours at 4° C.
  • the stock suspension was serially diluted, to 9.38 ⁇ g ml ⁇ 1 , by mixing 1 ml aluminium hydroxide-antigen suspension with 1 ml of aluminium hydroxide suspension, which had been previously adjusted for concentration, pH and osmolarity.
  • the samples were used for assaying after an overnight incubation under rocking motion at 4° C.
  • the aluminium hydroxide binding capacity (3000 ⁇ g ml ⁇ 1 in 10 mM histidine pH 6.5, 300 mOsm/L) was evaluated for several formulations of NadA at 50, 100, 200, 400, 800 and 1600 ml ⁇ 1 .
  • each formulation was centrifuged at 3000 g for 20 minutes and the supernatant was removed without disturbing the pellet.
  • the supernatants were treated with 0.5% deoxycholic acid sodium salt (DOC), incubated for 10 min at room temperature, followed by the addition of 60% trichloroacetic acid (TCA).
  • DOC deoxycholic acid sodium salt
  • the TCA pellets were re-suspended with sample buffer while the aluminium pellets were re-constituted with sample buffer containing 0.5 M Sodium phosphate at pH 8. Samples were loaded into a NUPAGE Novex 4-12% gradient Bis-Tris Midi gel and run under reducing conditions at a constant voltage of 200 V for approximately 50 minutes. The gels were stained-destained with colloidal blue staining kit.
  • NadA antigen is predominantly adsorbed to the aluminium hydroxide adjuvant. Any unabsorbed antigen in the formulation supernatant was below the limit of detection ( ⁇ 2%; FIG. 1 ). Furthermore, unabsorbed NadA in the formulation supernatant was not detectable at an antigen concentration of 800 ⁇ g/ml indicating ⁇ 98% adsorption at this antigen concentration.
  • Antigen was, however, detectable at 1600 ⁇ g/ml indicating that the adsorptive capacity of 1500 ⁇ g of aluminium hydroxide for NadA lies somewhere between 800 and 1600 ⁇ g/ml of NadA, and that at the clinical dose of 50 ⁇ g the amount of NadA adsorbed is significantly below the adsorptive capacity limit of the adjuvant of 1500 ⁇ g per dose in 10 mM histidine pH 6.5.
  • the assay utilized to analyse the NadA adsorbed to insoluble aluminium hydroxide was a three-step procedure: the saturation of the free sites on the aluminium hydroxide, the primary binding with an antibody that specifically recognizes the antigen NadA and the staining with a fluorescently labelled secondary antibody that binds to the first antibody.
  • BSA was added to the adsorbed component composition, followed by a 30 minute incubation at 4° C. using a vertical rotary mixer. After this step primary antibody was added, and followed by a further 30 minute incubation at 4° C. using a vertical rotary mixer. The secondary antibody was added followed by incubation for 20 minutes at room temperature without mixing, in the dark.
  • the blank, standard and check samples were placed on 96-microwell polypropylene plates.
  • the 75 ⁇ l/well suspensions were saturated with 25 ⁇ l of 10% BSA in 10 mM histidine buffer pH 6.5. After the incubation, plates were centrifuged (3000 g for 5 minutes) and the supernatants were removed.
  • the aluminium pellets were then washed and centrifuged twice with 100 ⁇ l of 10 mM histidine buffer pH 6.5.
  • the primary antibody rabbit anti-NadA
  • was pre-adsorbed with a goat serum diluted 1/10 in histidine buffer pH 6.5
  • the washed pellets were resuspended with 75 ⁇ l of histidine buffer pH 6.5 and 75 ⁇ l of primary antibody was subsequently added.
  • the samples were incubated and washed-centrifuged as previously described.
  • Adsorption of antigens to aluminium hydroxide adjuvants depends on pH, ionic strength and the presence of anions such as phosphate (reference 42). Therefore, it was necessary to evaluate the influence of the assay conditions on NadA adsorption.
  • the amount of antigen that is released from aluminium hydroxide during each of the blocking, staining and washing was measured in the supernatant of the assay sample after each of these steps (data not shown). Eluted antigen was not detectable in the supernatant until the incubation with the secondary antibody and the final washing step with PBS. Some antigen was displaced from aluminium hydroxide during the final wash with PBS. These were found to be in the range of 5% to 10% of antigen present in the formulation. Substitution of PBS with histidine buffer for this final wash was able to alleviate this effect with no detectable antigen released into the wash buffer (data not shown). The antigen loss following exchange to a PBS buffer was not found to have a significant effect of the predictive capability of the assay to determine, reliably and accurately, the concentration of antigen bound to the insoluble metal salt (see Table 3).
  • aluminium hydroxide was blocked with 2.5% BSA prior to staining with the primary and secondary antibodies.
  • This blocking was successful in limiting non-specific binding, as performing the flow cytometry assay in the absence of antigen with primary antibodies diluted 1:1000 and 1:10000 resulted in levels of fluorescence for the aluminium hydroxide particles 10-fold below levels observed for the complete assay with NadA formulated at 100 ⁇ g ml ⁇ 1 ( FIG. 3 a ).
  • the assay was performed with irrelevant primary antibodies not specific for NadA, the levels of fluorescence remained equal to those observed in the absence of antigen, indicating that unspecific binding between NadA and the fluorescently labelled secondary antibody is not significant ( FIG. 3 a ).
  • Standard formulations prepared from a stock solution of 300 ⁇ g ml ⁇ 1 for NadA and serially 2-fold diluted five times with aluminium hydroxide suspension, were analyzed by flow cytometry using both forward (FSC) and side scatter (SSC), parameters associated with particle size and morphology respectively. All standard formulations appeared as a single uniform population of particles ( FIGS. 4 a -4 c ), with increased concentration of adsorbed NadA having no impact on forward and side scatter measurements.
  • Antigen distribution of NadA on aluminium hydroxide aggregates was analyzed using SSC and relative fluorescence intensity (RFI). The analysis of the RFI revealed that when the suspension had no antigen adsorbed, 99% of the aggregates showed an RFI ⁇ 1000.
  • Standard formulations were prepared in the range of 0-100 ⁇ g ml ⁇ 1 and tested by the flow cytometry assay. Standard curves generated by three-parameter non-linear regression analysis had correlation coefficients R 2 >0.99 ( FIGS. 6 a -6 g ). To evaluate the reliability of the standard curves for measuring antigen concentrations, a series of test samples in the same concentration range were assayed and their protein concentration determined from fluorescence readings (Table 3). The results showed that the flow cytometry assay is accurate and reliable with overall percent accuracy of the test formulations in the range of 85% or greater.
  • Another advantage common to antibody based assays specific for a target antigen is the potential of the assay to be applied directly to complex formulations containing multiple antigens and adjuvants such as combination vaccines.
  • the assay was applied to a trivalent vaccine containing GNA2091-1870 and GNA2132-1030 in addition to NadA, and found no interference of these antigens in determining adsorbed concentrations of NadA.
  • the flow cytometry assay In addition to the accuracy, sensitivity and reproducibility of the flow cytometry assay possesses a number of other key advantages which stem from the fact that as flow cytometry analyses physical particles it is measuring the antigen directly on the surface of the aluminium particles. Firstly the degree of antigen adsorption to aluminium hydroxide is measured directly without the reliance on indirect measurements of unadsorbed antigen in formulation supernatants. Secondly, as the assay may be antibody based, it is possible for flow cytometry to be used to monitor antigen stability whilst still bound to the surface of insoluble metal salt adjuvants.
  • Flow cytometry (FC) based technology can be used for the direct detection of SMIPs on aluminium hydroxide with no need for labelling.
  • the assay was tested using a new class of TLR7 agonists which are analogs of the lead compound Compound A.
  • Benzonaphthyridine is the core scaffold of the series and the molecules have intrinsic fluorescence features.
  • Association of SMIPs with aluminium hydroxide transforms plain insoluble metal salt particles into particles that display fluorescent tags, detectable with flow cytometry by combining the light scattering properties with the intensity of fluorescence upon appropriate excitation.
  • Fluorescence spectroscopy confirmed that Compound A, Compound C, Compound B, Compound E and Compound H can be excited in the violet visible spectrum and emit fluorescence in the blue/green visible spectrum with slight differences in wavelength ( FIGS. 8 and 14 ).
  • FIGS. 9 a -9 d shows the results of these experiments for Compound C).
  • Aluminium hydroxide alone was gated to cover a homogeneous and compact population, which was based on screening tens of thousands of event to determine light scatter of light emitted by 488 nm blue laser source. Analysis of a solution of Compound C and the PBS control resulted in no detection of particles through light scattering over the background instrumental noise. The gate covered most of the particles of alum (more than 90%) and was applied to all other samples and used to evaluate fluorescence intensity. Filtration of SMIP solutions helped to avoid scatter of precipitated particles or co-precipitation of SMIPs and aluminium hydroxide when formulated together. Aluminium hydroxide alone was gated to cover an homogeneous and compact population ( FIG. 10 a ).
  • FIG. 10 b The gate was applied to Compound A and no overlapping of light scatter could be found ( FIG. 10 b ). When mixed together they still behave as two different populations ( FIG. 10 c ), in contrast to the single homogenous population observed when Compound C was adsorbed to aluminium hydroxide. Compound E also adsorbed to aluminium hydroxide and behaved as a single population ( FIGS. 15 a -15 d ).
  • Aluminium hydroxide particles included in the applied gate were analyzed for their fluorescence intensity at FACS Canto II using violet laser (405 nm) as excitation source and two different filters for emission: 525/50 nm and 450/50 nm ( FIGS. 10 a -10 c ).
  • SMIP-aluminium hydroxide formulation was treated with a 0.5M phosphate buffer (pH9) and the desorbed aluminium hydroxide was washed with either water (for soluble compounds) or butanol (for poorly water soluble compounds). The aluminium hydroxide was then analyzed again on FACS Canto II, using the same instrument settings, and showed no fluorescence like aluminium hydroxide alone ( FIGS. 11 a -11 n ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention utilizes the techniques and instruments which are typically used in flow cytometry (FC) as a tool for analyzing adsorbed materials. Thus the invention provides a method for analyzing a component which is adsorbed to an insoluble metal salt, comprising steps of: (i) labelling the adsorbed component with a binding reagent; and (ii) analyzing the labelled adsorbed component by flow cytometry.

Description

This application is the U.S. National Phase of International Application No. PCT/US2011/064938, filed Dec. 14, 2011 and published in English, which claims the benefit of U.S. Provisional Application No. 61/423,001 (filed Dec. 14, 2010), the complete contents of which are hereby incorporated herein by reference for all purposes.
TECHNICAL FIELD
The invention is in the field of analysing adsorbed material e.g. in vaccines.
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on Jun. 14, 2013, is named PAT54336_ASCII.TXT, and is 25,126 bytes in size.
BACKGROUND ART
Vaccine antigens are frequently adsorbed to insoluble metal salts, such as aluminium hydroxide and aluminium phosphate, to provide an adjuvant effect. It is often necessary to analyse antigens after their adsorption, but the adsorption itself can make analysis difficult e.g. as described in reference 1 for hepatitis B surface antigen (HBsAg).
Rather than testing adsorbed antigens directly, many assays instead rely on a desorption treatment, followed by analysis of the released antigen. For example, to measure the proportion of adsorbed antigen it is known to test for unadsorbed antigen before and after a desorption treatment, with the difference being used to infer the amount of adsorption. In this type of assay, however, the requirement for a desorption step is cumbersome, and it also means that the antigen is not being analysed in the form in which it is actually supplied or used.
Direct in situ quantification of adsorbed antigens has been reported e.g. by ELISA in reference 2, or by near-infrared spectroscopy in reference 3. Reference 4 discloses a direct alhydrogel formulation immunoassay (“DAFIA”) which is designed to directly (i.e. without prior extraction), accurately, sensitively, and specifically determine the content, identity and integrity of an antigen while it remains adsorbed to an aluminium hydroxide adjuvant.
It is an object of the invention to provide further and improved methods for analysing vaccine antigens (or other components) which are adsorbed to insoluble metal salts.
DISCLOSURE OF THE INVENTION
The invention utilises the techniques and instruments which are typically used in flow cytometry (FC) as a tool for analysing adsorbed materials. The invention provides in general a convenient way of analysing adsorbed components, which permits the analysis of individual particles of insoluble metal salts with components adsorbed to them to determine their properties, and from there to determine the average properties of a suspension of these particles.
A suspension of insoluble metal salt particles with adsorbed component(s) is passed through a flow cytometer to determine the properties of the individual particles. In a flow cytometer, each particle is passed through one or more beams of light, typically laser beams of set wavelength. A number of detectors are placed around the beam(s) of light. One detector is in line with the light beam in order to detect the forward scatter, and one or more may be perpendicular to the light beam, which detect the side scatter of the particle. Additionally, one or more detectors are situated near the light beam in order to detect light emitted from luminescent labels (e.g. fluorescent labels), which can be excited by the light beam. Typically, the wavelength of the light emitted from the luminescent label must differ from the wavelength of the light beam shone onto the particle, to ensure specific detection of the label. The degree of light scattering from the particle permits the size and morphology of the particle to be determined. The luminescence detector permits the detection of specific components adsorbed to the particle via the emission of a certain wavelength of light from a label attached to the adsorbed component. By using multiple labels, each of which emits a different wavelength of light, and each of which is specific for a single component, multiple adsorbed components in a single suspension of insoluble metal salt particles can be simultaneously analysed.
Thus the invention provides flow cytometry for the analysis of components adsorbed to an insoluble metal salt. In order to permit detection by the flow cytometer, the component must be labelled. In some embodiments, the adsorbed component contains an intrinsic label. In other embodiments, a detectable label is added by a binding reagent. Thus the invention provides a method for analysing a component which is adsorbed to an insoluble metal salt, comprising steps of: (i) labelling the adsorbed component with a binding reagent to produce a labelled adsorbed component; and (ii) analysing the labelled adsorbed component by flow cytometry.
This method is advantageous over many of the methods in the prior art because it is not necessary to desorb the component which is adsorbed to the insoluble metal salt. Instead, the adsorbed component can be analysed while it is still attached to the insoluble metal salt. In addition to the removal of the need for desorption, analysis in situ may in some circumstances also permit the determination of the activity of the adsorbed component.
The invention also provides a flow cytometer comprising a labelled component adsorbed to an insoluble metal salt. The invention also provides a cytometer sample tube comprising a labelled component adsorbed to an insoluble metal salt.
In practice, typically a large batch of insoluble metal salt adsorbed component is made. A sample of this batch is then analysed by the method of the invention.
The method of the invention can be illustrated using an example of a protein as the adsorbed component, and first and second antibodies as the binding reagent. As set out above, a blocking step which comprises incubating the adsorbed component in BSA may be performed. This ensures that any unoccupied binding sites on the insoluble metal salt are occupied, so preventing the adsorption of any binding reagents to the insoluble metal salt. Next, the adsorbed component is incubated with a first reagent, in this example an antibody, which binds to the adsorbed protein and not to any other components used in the assay. This step is followed by the addition of a second reagent, which comprises a label capable of being detected by the flow cytometer, and which binds specifically to the first reagent, for example a fluorescently labelled antibody binding to the first antibody (e.g. by binding to the Fc region of the first antibody, so that if the first antibody is a goat antibody, the second antibody should be an anti-goat antibody from another species). Wash steps are incorporated as necessary between the binding steps.
The method of analysing an adsorbed component by flow cytometry may comprise one or more additional steps prior to passing the adsorbed component through the flow cytometer. Thus the invention provides a method of analysing an adsorbed component comprising one or more of the steps of:
    • synthesising insoluble metal salt particles;
    • suspending the insoluble metal salt particles in a liquid;
    • synthesising one or more components for adsorption;
    • combining insoluble metal salt particles with one or more components for adsorption;
    • incubating a combination of insoluble metal salt particles with one or more components for adsorption under conditions which permit adsorption of the component onto the insoluble metal salt particles;
    • combining the suspension of adsorbed component on an insoluble metal salt with one or more further components, for example components adsorbed on an insoluble metal salt which optionally may have already been analysed by the flow cytometry method of the invention;
    • dilution or concentration of the one or more components adsorbed to the insoluble metal salt;
    • filtering the suspension of adsorbed component on an insoluble metal salt;
    • exchanging the solvent in which the particles are suspended, which may be the exchange from a non-aqueous solvent to an aqueous solvent (and vice versa) or the exchange of the buffer component of an aqueous solvent;
    • taking a sample of the batch of adsorbed component;
    • adding a preservative to the suspension of the adsorbed component on an insoluble metal salt;
    • adding a physiological salt to the suspension of adsorbed component on an insoluble metal salt;
    • altering the pH of the suspension of adsorbed component on an insoluble metal salt;
    • altering the osmolality of the suspension of adsorbed component on an insoluble metal salt;
    • sterilising the suspension of adsorbed component on an insoluble metal salt;
    • removing endotoxin from a suspension of adsorbed component on an insoluble metal salt;
    • adding a blocking reagent; and/or
    • adding one of more binding reagents;
      and the step of analysing the adsorbed component by flow cytometry.
The order of steps listed above is not a strict indication of the order in which they are to be performed in the method, but provides one example in which they can be combined. It is well within the capabilities of the skilled person, following the teachings herein, to generate further methods of analysis by the rearrangement and/or repetition of one or more steps. Many of the steps (e.g. sampling, adjusting the pH, diluting or concentrating etc.) may be performed more than once at different stages.
The measurement by flow cytometry, however, provides data only on the degree of adsorption of the component to the insoluble metal salt at the time of assay. In practice, pharmaceutical compositions may be kept for months, and often years, before use. It is well known that adsorbed components can become desorbed from insoluble metal salts over time, and this desorption depends on the particular insoluble metal salt, adsorbed component and buffer, inter alia. The method of the present invention can therefore be used repeatedly over time to assay further samples from the same batch of component adsorbed to an insoluble metal salt to determine the stability of the adsorption interaction. A range of variables (buffer composition, temperature, osmolality etc.) can be tested to determine the optimum conditions for storage of a composition and the degree of adsorption easily and quickly determined using the method of the invention. Thus the invention provides a method of determining the stability of an adsorbed component comprising determining the degree of adsorption of a component to a metal salt by flow cytometry and repeating the flow cytometry analysis one or more times.
As noted above, the results from the analysis of the component adsorbed to the insoluble metal salt can determine if a number of downstream steps are undertaken. The properties of the analysed adsorbed component are typically compared to predetermined parameters. These parameters can be wide ranging. For instance, for a particular composition, particular sizes of insoluble metal salt particle may be preferred, particular ratios of insoluble metal salt to adsorbed component may be preferred or particular ratios of adsorbed components if the assayed composition comprises more than one, or stability for a particular period of time under specific conditions is required. The particular parameters which must be met are, of course, dependent upon the insoluble metal salt, adsorbed component, buffer, and the ultimate use of the adsorbed component.
The method of the invention has many applications. For instance, it can form a quality control step in a manufacturing and distributing process. Thus the invention provides a method of manufacturing a composition comprising the step of analysing a labelled adsorbed component by flow cytometry and one or more of the steps of:
    • calculating one or more parameters from the data acquired in the flow cytometry analysis, for example particle size distribution, % adsorption of the component to the insoluble metal salt and/or distribution of the antigen on the metal particles;
    • deciding to proceed with manufacturing a composition incorporating the assayed batch of adsorbed component on the basis of the results of the flow cytometry analysis;
    • combining the suspension of adsorbed component on an insoluble metal salt with one or more further components, for example components adsorbed on an insoluble metal salt which may have also been analysed by the flow cytometry method of the invention;
    • filtering the suspension of adsorbed component on an insoluble metal salt;
    • exchanging the solvent in which the particles are suspended, which may be the exchange from a non-aqueous solvent to an aqueous solvent (and vice versa) or the exchange of the buffer component of an aqueous solvent;
    • adding a preservative to the suspension of the adsorbed component on an insoluble metal salt;
    • adding a physiological salt to the suspension of adsorbed component on an insoluble metal salt;
    • altering the pH of the suspension of adsorbed component on an insoluble metal salt;
    • altering the osmolality of the suspension of adsorbed component on an insoluble metal salt;
    • sterilising the suspension of adsorbed component on an insoluble metal salt;
    • removing endotoxin from a suspension of adsorbed component on an insoluble metal salt;
    • lyophilising a suspension of adsorbed component on an insoluble metal salt;
    • resuspending a lyophilisate of adsorbed component on an insoluble metal salt;
    • dividing the suspension of adsorbed component on an insoluble metal salt into smaller volumes;
    • preparing a unit dose of the suspension of adsorbed component on an insoluble metal salt;
    • formatting a unit dose of the suspension of adsorbed component on an insoluble metal salt as an injectable; and/or
    • packaging a unit dose of the suspension of adsorbed component on an insoluble metal salt, optionally with instructions for use.
The order of steps listed above is not an indication of the order in which they are to be performed in the method of manufacture. Indeed, many of the steps (e.g. sampling, adjusting the pH, dilution or concentrating etc.) may be performed more than once at different stages in the manufacturing method. The step of analysing the adsorbed component can be performed at nearly any stage in the method, and provides important information at each point. Indeed, it can be performed multiple times. For instance, a change in the buffer or the pH of the suspension to one suitable for a composition for use as a pharmaceutical may interfere with the adsorption interaction, or may cause the particles of insoluble metal salt to aggregate to a greater or lesser degree. By analysing a sample of the suspension comprising the adsorbed component prior to and following a step in the method, the precise effect of that step can be simply and quickly determined. Following its manufacture (which includes the step of analysis by flow cytometry), the adsorbed component, optionally in the form of a composition, can be distributed. Thus the invention provides a method of distributing an adsorbed component, or composition comprising the adsorbed component, comprising a method of flow cytometry or a method of manufacture as set out above and the step of distributing the adsorbed component or composition comprising the adsorbed component.
The Sample
A sample of this batch will then be analysed by the method of the invention. The sample is typically less than 100 ml, for example less than 50 ml, less than 40 ml, less than 30 ml, less than 20 ml, less than 10 ml, less than 5 ml, less than 4 ml, less than 3 ml, less than 2 ml, less than 1 ml, or less than 0.5 ml. The sample is typically at least 100 μl, for example at least 200 μl, at least 300 μl, at least 400 μl, at least 500 μl, at least 600 μl, at least 700 μl, at least 800 μl, at least 900 μl, at least 1 ml, at least 2 ml, at least 3 ml, at least 4 ml, or at least 5 ml. The batch of insoluble metal salt adsorbed component may be of a different concentration to the concentration of insoluble metal salt and/or adsorbed component that is suitable for analysis by the flow cytometry method of the invention. Therefore it may be necessary to dilute or concentrate the suspension as necessary to achieve the desired concentration of insoluble metal salt and/or adsorbed component. Typically flow cytometry analysis is performed on suspensions with a particle concentration of about 103-109 particles ml−1, for example 104-108 particles ml−1, 105-107 particles ml−1 such as about 106 particles ml−1. The concentration of insoluble metal salt may range from about 10 μg ml−1-about 100 mg ml−1, for example about 100 μg ml−1-about 10 mg ml−1, about 500 μg ml−1-about 5 mg ml−1, such as about 1000 to about 2000 μg ml−1. Similarly the concentration of adsorbed component may vary, but will typically be about 1 μg ml−1-about 10 mg ml−1, for example about 10 μg ml−1-about 1 mg ml−1, about 25 μg ml−1-about 500 μg ml−1, such as about 50 μg ml−1 to about 150 μg ml−1
Determination of Adsorption
The adsorbed component is detected through a specific label. This label may be part of the adsorbed component, for example a portion of a small molecule which contains a region of conjugated bonds, as detailed further below. In an alternative, the label may be attached to the adsorbed component through a binding reagent. Binding reagents and labels for use in the method of the invention are discussed in more detail below.
When the component is adsorbed to the insoluble metal salt, the insoluble metal salt particle can then be detected through the adsorbed component, either by the intrinsic label or by the one or more binding reagents used to attach a label. Thus an insoluble metal salt particle which has one or more components adsorbed to it can be distinguished from an insoluble metal salt particle which has no components attached to it. Thus the present method permits the determination of the antigen distribution on the insoluble metal salt suspension.
The determination of the distribution of adsorption is important to ensure that the optimum ratio of component and adjuvant has been reached, for example to ensure complete adsorption with minimum loss of excess antigen, or to ensure the maximal in vivo response.
Analysis of Suspensions Containing Multiple Adsorbed Components
The method of the invention can be used to specifically analyse a single antigen in a suspension of multiple adsorbed components. The method may also be used to simultaneously analyse multiple species of adsorbed component in a suspension. The suspension may contain insoluble metal salt particles with multiple different adsorbed components. This suspension may be generated by the addition of a solution containing the different species of component for adsorption to the insoluble metal salt suspension. In an alternative, the suspension of multiple absorbed components may comprise insoluble metal salt particles each of which has only one species of component adsorbed to it. This suspension may be generated by adsorbing each component to the insoluble metal salt in isolation before combining them.
In essence, the method for analysing multiple adsorbed components comprises the performance of the method of the invention multiple times in parallel. Following the optional blocking step, if required, multiple binding reagents are added, simultaneously or serially, each binding reagent being specific in its binding for a different adsorbed component. The result of the addition of the binding reagents is the linking of a different detectable label to each different adsorbed component, thus permitting the detection of each adsorbed component in isolation from the remaining components of the suspension. In an alternative, one binding reagent may bind to all adsorbed components. This alternative would permit the detection of the total amount of adsorption by the different adsorbed component to the insoluble metal salt.
In one embodiment, the multiple species of adsorbed component are adsorbed to the same metal salt (e.g. aluminium hydroxide). In another embodiment, the species are adsorbed to different metal salts, for example in a suspension comprising two adsorbed components, the first component is adsorbed to aluminium hydroxide and the second component is adsorbed to aluminium phosphate.
Binding Reagents
The methods of the invention typically require the use of a binding reagent which is used to label the adsorbed component. The binding reagent may be a single reagent, or may comprise two or more reagents. If the binding reagent comprises more than one reagent, these reagents may be added simultaneously or sequentially. If a binding reagent is used, the first reagent is a compound which binds to the adsorbed component, usually specifically to that adsorbed component. If the adsorbed compound is a protein or a carbohydrate, the first reagent may be an antibody which binds to the component. If the adsorbed component is a receptor, the first reagent may be a ligand which binds to that receptor (or vice versa). If the adsorbed compound is a carbohydrate, the first reagent may be a lectin.
The binding of a reagent to the adsorbed component may in some instances be used indicate that the component is in a biologically active from. If a particular conformation of the component is known to be necessary for the biological activity of the component, then by using an antibody which binds only to an epitope present in the active form, the active form can be specifically labelled and thus detected. Similarly, if the component is a ligand, and it can be bound by its cognate receptor, then this may be indication that the adsorbed component is in a biologically active configuration.
The first reagent may be linked to a label which is detectable by the flow cytometer, in which instance the first reagent will typically be the only reagent. In an alternative, the first reagent may be linked to a label which is not detectable by the flow cytometer, i.e. a tag, for instance one partner of a typical affinity pairing (e.g. biotin and avidin), or a sequence tag such as a His6, myc or FLAG tag. In a further alternative, the first reagent is not labelled. Typically, if the first reagent comprises a detectable label, then a second reagent is not required. If the first reagent is linked to a non-detectable label or is not labelled, then a second reagent is typically employed.
The second reagent usually comprises a label which is detectable by the flow cytometer. The second reagent is capable of binding to the first reagent. The second reagent is often an antibody with affinity for the first reagent. In the case where the first reagent is an antibody, the second reagent is typically an antibody which binds to the first antibody (i.e. if the first reagent was a goat antibody, the second reagent should be an anti-goat antibody). As detailed above, in some instances the first reagent comprises a label which is not detectable by the flow cytometer. In this situation, the second reagent can bind specifically to the label of the first reagent, for instance if the non-detectable label on the first reagent is a FLAG tag, the second reagent is ideally an anti-FLAG antibody.
If the binding reagent is an antibody it may be a polyclonal antibody or a monoclonal antibody. It is preferred to use a monoclonal antibody where binding to a specific epitope is desired, for instance in the situation where specifically an active form of adsorbed component is being labelled. Antibodies of the invention can be of any isotype (e.g. IgA, IgG, IgM i.e. an α, γ or μ heavy chain) and may have a κ or a λ light chain. The antibody may be derived from a variety sources, for example human, cow, rat, mouse, pig, goat, rabbit, camel, sheep, guinea pig, snake, frog, llama, carp, shark, dog, cat, duck ostrich or chicken.
Although typically a binding reagent comprising more than one reagent will be composed of two reagents, there is no upper limit to the number of reagents. All that is required is that each reagent of the binding reagent should bind to the preceding reagent, and ultimately introduce a label which is specifically bound to the adsorbed component. Thus the binding reagent may comprise one, two, three, four, five, six, seven, eight, nine, ten or more than ten reagents.
Labels for Detection by the Flow Cytometer
If the adsorbed component is not intrinsically fluorescent (i.e. it does not autofluoresce) then, as detailed previously, it is necessary to use one or more binding reagents which comprise a label which can be detected by the flow cytometer. Typically this will be a luminescent label, for example a fluorescent label. A wide range of fluorescent labels exist which are compatible with the method of the invention. Selection of an appropriate label is dependent upon any intrinsic absorption and emission spectra of the insoluble metal salt, the adsorbed component(s), and any other reagents used in the assay. The intrinsic fluorescence of the components can be simply determined by passing the assay components through the flow cytometer without the detectable label, as described herein.
Labels should be selected with absorption and emission spectra which do not interfere, or do not interfere to a significant extent, with those of the assay components. The spectra do not interfere to a significant degree if the labelled adsorbed component can be specifically and sensitively detected when it passes through the flow cytometer.
A wide range of labels spanning the spectrum of visible light are available (see Table 1 for a non-limiting list of fluorescent labels). Further labels and a guide to fluorescent labelling may be found in reference 5. Selection of a suitable label or combination of labels is well within the capability of the skilled person following the teachings herein.
Detection without Binding Reagents
As noted previously, some adsorbed compounds may intrinsically fluoresce, a phenomenon also termed autofluorescence. When such a compound is adsorbed to an insoluble metal salt, the use of one or more binding reagents to label the adsorbed component is not required to permit the detection of the adsorbed complex by flow cytometry. Instead, flow cytometry analysis can be performed immediately following adsorption. Optionally one or more wash steps to remove unbound adsorbed component from the insoluble metal salt particles may be employed. Intrinsically fluorescent adsorbed components typically contain conjugated systems, i.e. a system of connected p-orbitals in a series of alternating single and double bonds, which allow delocalisation of pi electrons. The conjugated system may be aromatic, non-aromatic or anti-aromatic.
An exemplary class of autofluorescent molecules comprises a benzonaphthyridine scaffold, for example SMIPs which are analogs of Compound A. A number of analogs of Compound A are displayed in Table 2, including compounds B to H. Any of the general and specific compounds in references 6 can be analysed using the invention, as can other autofluorescent molecules (in particular SMIPs) which comprise a phosphonate group (or a phosphinate, a phosphonite, a phosphinite, or a phosphate group) and which can adsorb to insoluble metal salts.
The autofluorescent adsorbed component may be a protein. Fluorescence by a protein may be the result of intrinsic fluorescence of tryptophan residues in that protein, though a lesser contribution to fluorescence may be made by tyrosine and phenylalanine residues. The three residues have distinct absorption and emission maxima, which are typically as follows: tryptophan absorbs at 280 nm and fluoresces at 348 nm, tyrosine absorbs at 274 nm and fluoresces at 303 nm and phenylalanine absorbs at 257 nm and fluoresces at 282 nm. The exact absorption and fluorescence wavelengths of the residue depend on the local chemical environment of the residue. Tryptophan residues which are in hydrophobic regions of a proteins, for instance the core, can have spectra which are shifted by 10 to 20 nm compared to a tryptophan in the hydrophilic regions, e.g. the surface, of the protein.
If the component is a protein which is associated with a cofactor, then the fluorescence of that cofactor may be used as a label to detect the component. NADH and/or NADPH are cofactors for a number of proteins, and have approximate absorption and fluorescence maxima at 340 nm and 460 nm respectively. Riboflavin, FMN and FAD absorb at approximately 450 nm and fluoresce at approximately 525 nm. Other cofactors are based on a porphyrin ring. Proteins comprising a porphyrin ring include heme containing proteins and chlorophyll containing proteins.
Some components may comprise intrinsic fluorophores which are not cofactors. For example, green fluorescent protein (GFP) and its derivatives comprise an imidazolin-5-one heterocyclic ring fluorophore formed from the tripeptide Thr-Tyr-Gly present in the primary sequence of the protein.
In some embodiments, the invention encompasses methods in which there are multiple adsorbed components, at least one of which is autofluorescent and at least one of which is labeled using a binding reagent e.g. an embodiment in which both an antigen and a compound of Table 2 are adsorbed to a metal salt.
Blocking
In some suspensions that are analysed by the method of the invention, it is envisaged that some of the sites capable of binding components on the insoluble metal salt will not be occupied by the adsorbed component. In this instance, a further step to block the free sites prior to the addition of a binding reagent may be performed. By blocking is meant the addition of a further reagent which is capable of adsorption to the insoluble metal salt, but which differs from the adsorbed component and which is not recognised by a binding reagent. This ensures that the risk of the binding sites which remain on the insoluble metal salt following adsorption of the adsorbed component being occupied by the binding reagent is minimised or eliminated. Non-specific binding, i.e. adsorption, of the binding reagent to the insoluble metal salt should be avoided because it can lead to a reduction in the sensitivity and specificity of the method. A typical reagents used to block binding sites on the insoluble metal salt includes one or more of BSA, newborn calf serum, casein, casein digest, milk powder (e.g. skimmed milk powder), chick albumin, rabbit serum, horse serum, goat serum, mouse serum, human serum, rat serum, pig serum, Block Ace (Serotec), E. coli extract, pig skin gelatin, fish skin gelatin, steelhead salmon serum, Protein-Free Blocking Buffer (Pierce), salmon sperm DNA and randomly sheared genomic DNA. Thus the invention provides a method further comprising the step of blocking the insoluble metal salt, prior to the addition of the binding reagent.
Washing
Usually a wash step comprises centrifuging the insoluble metal salt particles to form a pellet, aspirating the supernatant and replacing it with a fresh buffer solution. The suspension is then passed through the flow cytometer which is able to detect the size of the particle (thus providing information on the number of insoluble metal salt particles in the desired size range and also excluding any aggregates of binding reagent from analysis) and also any luminescence from the label bound to the adsorbed component (which permits differentiation between insoluble metal salt particles which have component adsorbed to them, and those which do not, and also the degree of adsorption). Thus the proportion of the particles in the suspension which are of appropriate size and which also fluoresce appropriately (indicating the presence of the adsorbed component) can be determined. This information can then be used to determine whether or not the batch of material which has been assayed is suitable for use in downstream processes.
Insoluble Metal Salts
As disclosed herein, components can adsorb to insoluble metal salts, thereby forming an adsorbed complex. For instance, they can be adsorbed to insoluble calcium salts (e.g. calcium phosphate) or, preferably, to insoluble aluminium salts. Such aluminium salts have a long history of use in vaccines. Aluminium salts which include hydroxide ions are the preferred insoluble metal salts for use with the present invention.
Useful aluminium salts include, but are not limited to, aluminium hydroxide, aluminium oxyhydroxide, and aluminium hydroxyphosphates (including aluminium hydroxyphosphate sulfate). Such salts are described e.g. in chapters 8 & 9 of reference 7.
Preferred salts for adsorption of components are aluminium oxyhydroxides and/or aluminium hydroxyphosphate. These have surface hydroxyl moieties which can readily undergo ligand exchange with phosphorus-containing groups (e.g. phosphates, phosphonates) to provide stable adsorption.
The adjuvants commonly known as “aluminium hydroxide” are typically aluminium oxyhydroxide salts, which are usually at least partially crystalline. Aluminium oxyhydroxide, which can be represented by the formula AlO(OH), can be distinguished from other aluminium compounds, such as aluminium hydroxide Al(OH)3, by infrared (IR) spectroscopy, in particular by the presence of an adsorption band at 1070 cm−1 and a strong shoulder at 3090-3100 cm−1 (chapter 9 of ref. 7). The degree of crystallinity of an aluminium hydroxide adjuvant is reflected by the width of the diffraction band at half height (WHH), with poorly-crystalline particles showing greater line broadening due to smaller crystallite sizes. The surface area increases as WHH increases, and adjuvants with higher WHH values have been seen to have greater capacity for antigen adsorption. A fibrous morphology (e.g. as seen in transmission electron micrographs) is typical for aluminium hydroxide adjuvants. The pI of aluminium hydroxide adjuvants is typically about 11 i.e. the adjuvant itself has a positive surface charge at physiological pH. Adsorptive capacities of between 1.8-2.6 mg protein per mg Al+++ at pH 7.4 have been reported for aluminium hydroxide adjuvants.
The adjuvants commonly known as “aluminium phosphate” are typically aluminium hydroxyphosphates, often also containing a small amount of sulfate (i.e. aluminium hydroxyphosphate sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt. Hydroxyphosphates generally have a PO4/Al molar ratio between 0.3 and 1.2. Hydroxyphosphates can be distinguished from strict AlPO4 by the presence of hydroxyl groups. For example, an IR spectrum band at 3164 cm−1 (e.g. when heated to 200° C.) indicates the presence of structural hydroxyls (chapter 9 of reference 7).
The PO4/Al3+ molar ratio of an aluminium phosphate adjuvant will generally be between 0.3 and 1.2, preferably between 0.8 and 1.2, and more preferably 0.95±0.1. The aluminium phosphate will generally be amorphous, particularly for hydroxyphosphate salts. A typical adjuvant is amorphous aluminium hydroxyphosphate with PO4/Al molar ratio between 0.84 and 0.92, included at 0.6 mg Al3+/ml. The aluminium phosphate will generally be particulate (e.g. plate-like morphology as seen in transmission electron micrographs). Typical diameters of the particles are in the range 0.5-20 μm (e.g. about 5-10 μm) after any antigen adsorption. Adsorptive capacities of between 0.7-1.5 mg protein per mg Al+++ at pH 7.4 have been reported for aluminium phosphate adjuvants.
The point of zero charge (PZC) of aluminium phosphate is inversely related to the degree of substitution of phosphate for hydroxyl, and this degree of substitution can vary depending on reaction conditions and concentration of reactants used for preparing the salt by precipitation. PZC is also altered by changing the concentration of free phosphate ions in solution (more phosphate=more acidic PZC) or by adding a buffer such as a histidine buffer (makes PZC more basic). Aluminium phosphates used according to the invention will generally have a PZC of between 4.0 and 7.0, more preferably between 5.0 and 6.5 e.g. about 5.7.
A composition including a component adsorbed to an insoluble metal salt can also include a buffer (e.g. a phosphate or a histidine or a Tris buffer).
Because of the insolubility of adsorptive metal salts which are useful with the invention, compositions containing adsorbed components will generally be suspensions having a cloudy appearance. This can mask contaminating bacterial growth and so the method of manufacturing a composition from a batch an adsorbed component (which has been assayed by flow cytometry) may include the step of adding a preservative such as thiomersal or 2-phenoxyethanol. It is preferred that a composition should be substantially free from (e.g. <10 μg/ml) mercurial material e.g. thiomersal-free. Methods of manufacturing a composition containing no mercury are more preferred. Thus a method of the invention may comprise the step of removing mercurial material from a suspension of adsorbed component.
A composition can include a mixture of both an aluminium oxyhydroxide and an aluminium hydroxyphosphate, and adsorbed components may be adsorbed to one or both of these salts.
The concentration of Al+++ in a composition for administration to a patient is preferably less than 10 mg/ml e.g. ≦5 mg/ml, ≦4 mg/ml, ≦3 mg/ml, ≦2 mg/ml, ≦1 mg/ml, etc. A preferred range is between 0.3 and 1 mg/ml. A maximum of <0.85 mg/dose is preferred. The concentration of Al+++ in the pharmaceutical composition may differ from the concentration in the suspension analysed by the flow cytometry method of the invention.
Immunogens
The invention is particularly useful for assaying adsorbed components in, or for incorporation into, immunogenic compositions. Adsorbed components assayed by the method of the invention may be useful during immunisation.
The invention can be used with a wide range of adsorbed components which can be used for treating or protecting against a wide range of diseases. The adsorbed component may elicit an immune response that protects against a viral disease (e.g. due to an enveloped or non-enveloped virus), a bacterial disease (e.g. due to a Gram negative or a Gram positive bacterium), a fungal disease, a parasitic disease, an auto-immune disease, or any other disease. The adsorbed component may also be useful in immunotherapy e.g. for treating a tumour/cancer, Alzheimer's disease, or an addiction.
The adsorbed component may take various forms e.g. a whole organism, an outer-membrane vesicle, a polypeptide, a saccharide, a liposaccharide, a conjugate (e.g. of a carrier and a hapten, or of a carrier and a saccharide or liposaccharide), etc. Where the adsorbed component is a polypeptide, it will typically be a surface polypeptide e.g. an adhesin, a hemagglutinin, an envelope glycoprotein, a spike glycoprotein, etc.
The adsorbed component may elicit an immune response against an influenza virus, including influenza A and B viruses. Various forms of influenza virus immunogen are currently available, typically based either on live virus or on inactivated virus. Inactivated vaccines may be based on whole virions, split virions, or on purified surface antigens. Influenza antigens can also be presented in the form of virosomes. Hemagglutinin is the main adsorbed component in current inactivated vaccines, and vaccine doses are standardised by reference to HA levels, typically measured by SRID. Existing vaccines typically contain about 15 μg of HA per strain, although lower doses can be used e.g. for children, or in pandemic situations, or when using an adjuvant. Fractional doses such as ½ (i.e. 7.5 μg HA per strain), ¼ and ⅛ have been used, as have higher doses (e.g. 3× or 9× doses [8,9]). Thus compositions may include between 0.1 and 150 μg of HA per influenza strain, preferably between 0.1 and 50 μg e.g. 0.1-20 μg, 0.1-15 μg, 0.1-10 μg, 0.1-7.5 μg, 0.5-5 μg, etc. Particular doses include e.g. about 45, about 30, about 15, about 10, about 7.5, about 5, about 3.8, about 3.75, about 1.9, about 1.5, etc. per strain. It is usual to include substantially the same mass of HA for each strain included in the vaccine e.g. such that the HA mass for each strain is within 10% of the mean HA mass per strain, and preferably within 5% of the mean. For live vaccines, dosing is measured by median tissue culture infectious dose (TCID50) rather than HA content, and a TCID50 of between 106 and 108 (preferably between 106.5-107.5) per strain is typical. Rather than use SPF eggs as the substrate for viral growth, where virus is harvested from infected allantoic fluids of hens' eggs, cell lines that support influenza virus replication may be used. The cell line will typically be of mammalian origin e.g. MDCK. Influenza A virus adsorbed components may be from any suitable HA subtype strain e.g. H1, H3, H5, H7, H9 etc., such as a H1N1, H3N2 and/or H5N1 strain.
The adsorbed component may elicit an immune response against a Candida fungus such as C. albicans. For instance, the adsorbed component may be a β-glucan, which may be conjugated to a carrier protein. The glucan may include β-1,3 and/or β-1,6 linkages. Suitable adsorbed components include those disclosed in references 10 & 11.
The adsorbed component may elicit an immune response against a Streptococcus bacterium, including S. agalactiae, S. pneumoniae and S. pyogenes. For instance, the adsorbed component may be a capsular saccharide, which may be conjugated to a carrier protein. For S. agalactiae the saccharide may be from one or more of serotypes Ia, Ib, II, III, and/or V. For S. pneumoniae the saccharide may be from one or more of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and/or 23F. In addition to (or in place of) capsular saccharide immunogen(s), polypeptide adsorbed components may be used to elicit a protective anti-streptococcal immune response e.g. comprising RrgB, as disclosed in reference 12.
The adsorbed component may elicit an immune response against a Staphylococcus bacterium, including S. aureus or S. epidermidis. For instance, the immunogen may comprise an IsdA antigen, an IsdB antigen, a ClfA antigen, a ClfB antigen, a SdrD antigen, a Spa antigen, an EsxA antigen, an EsxB antigen, a Sta006 antigen, a hemolysin, and/or a Sta011 antigen. Suitable S. aureus immunogens and their combinations are disclosed in reference 13.
The adsorbed component may elicit an immune response against a meningococcal bacterium (Neisseria meningitidis). For instance, the adsorbed component may be a capsular saccharide, which may be conjugated to a carrier protein. Capsular saccharides are particularly useful for protecting against meningococcal serogroups A, C, W135 and/or Y. In addition to (or in place of) capsular saccharide adsorbed component(s), polypeptide adsorbed components and/or outer membrane vesicles may be used to elicit a protective anti-meningococcal immune response, particularly for use against serogroup B e.g. as disclosed in reference 14.
The adsorbed component may elicit an immune response against a hepatitis virus, such as a hepatitis A virus, a hepatitis B virus, a hepatitis C virus and/or a hepatitis E virus. For instance, the adsorbed component may be hepatitis B virus surface antigen (HBsAg).
The adsorbed component may elicit an immune response against a respiratory syncytial virus. Adsorbed components may be from a group A RSV and/or a group B RSV. Suitable immunogens may comprise the F and/or G glycoproteins or fragments thereof e.g. as disclosed in references 15 & 16.
The adsorbed component may elicit an immune response against a Chlamydia bacterium, including C. trachomatis and C. pneumoniae. Suitable adsorbed components include those disclosed in references 17-23.
The adsorbed component may elicit an immune response against an Escherichia coli bacterium, including extraintestinal pathogenic strains. Suitable adsorbed components include those disclosed in references 24-26.
The adsorbed component may elicit an immune response against a coronavirus, such as the human SARS coronavirus. Suitable adsorbed components may comprise the spike glycoprotein.
The adsorbed component may elicit an immune response against a Helicobacter pylori bacterium. Suitable adsorbed components include CagA [27-30], VacA [31,32], and/or NAP [33-35].
The adsorbed component may elicit an immune response against rabies virus. A suitable adsorbed component is an inactivated rabies virus [36, RabAvert™].
The adsorbed component may elicit an immune response against a human papillomavirus. Useful immunogens are L1 capsid proteins, which can assemble to form structures known as virus-like particles (VLPs). The VLPs can be produced by recombinant expression of L1 in yeast cells (e.g. in S. cerevisiae) or in insect cells (e.g. in Spodoptera cells, such as S. frugiperda, or in Drosophila cells). For yeast cells, plasmid vectors can carry the L1 gene(s); for insect cells, baculovirus vectors can carry the L1 gene(s). More preferably, the composition includes L1 VLPs from both HPV-16 and HPV-18 strains. This bivalent combination has been shown to be highly effective [37]. In addition to HPV-16 and HPV-18 strains, it is also possible to include L1 VLPs from HPV-6 and HPV-11 strains.
The adsorbed component may elicit an immune response against a tumour antigen, such as MAGE-1, MAGE-2, MAGE-3 (MAGE-A3), MART-1/Melan A, tyrosinase, gp100, TRP-2, etc. The adsorbed component may elicit an immunotherapeutic response against lung cancer, melanoma, breast cancer, prostate cancer, etc.
The adsorbed component may elicit an immune response against a hapten conjugated to a carrier protein, where the hapten is a drug of abuse [38]. Examples include, but are not limited to, opiates, marijuana, amphetamines, cocaine, barbituates, glutethimide, methyprylon, chloral hydrate, methaqualone, benzodiazepines, LSD, nicotine, anticholinergic drugs, antipsychotic drugs, tryptamine, other psychomimetic drugs, sedatives, phencyclidine, psilocybine, volatile nitrite, and other drugs inducing physical and/or psychological dependence.
Various other adsorbed components may be used.
Compositions for Immunisation against Neisseria meningitidis
The flow cytometry method of the invention is particularly useful for assaying adsorbed components in immunogenic compositions for immunising against meningococcus e.g. against serogroup B.
Preferred immunogenic compositions prepared by the method of manufacturing disclosed herein comprise: (i) an aluminium hydroxide adjuvant; (ii) compound 1, 2 or 5 herein; (iii) a first polypeptide comprising SEQ ID NO: 1; (iv) a second polypeptide comprising SEQ ID NO: 2; and (v) a third polypeptide comprising SEQ ID NO: 3, 4 or 5; wherein compound of (ii) is adsorbed to the aluminium hydroxide.
The polypeptides used with the invention may, compared to the SEQ ID NOs herein, include one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, etc.) amino acid substitutions, such as conservative substitutions (i.e. substitutions of one amino acid with another which has a related side chain). Genetically encoded amino acids are generally divided into four families: (1) acidic i.e. aspartate, glutamate; (2) basic i.e. lysine, arginine, histidine; (3) non-polar i.e. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar i.e. glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In general, substitution of single amino acids within these families does not have a major effect on the biological activity. The polypeptides may also include one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, etc.) single amino acid deletions relative to the SEQ ID NO sequences. The polypeptides may also include one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, etc.) insertions (e.g. each of 1, 2, 3, 4 or 5 amino acids) relative to the SEQ ID NO sequences.
Ideally, 1 2 or 3 of the first second and/or third polypeptides is/are also adsorbed to the aluminium hydroxide. These polypeptides are disclosed in more detail in references 14 and 39. The composition produced by the method of manufacturing may include 5-100 μg of each polypeptide. The composition ideally does not include any bacterial outer membrane vesicles.
The composition produced by the method of manufacturing may include from 5-100 μg of compound 1, 2 or 5. For example, it may include from 5-100 μg of compound 2, or it may include from 5-100 μg of compound 5.
The composition may include a histidine buffer e.g. a 10 mM histidine buffer. It may include sucrose and/or sodium chloride. It may be administered in a dosage volume of 0.5 ml e.g. for intramuscular injection.
Agonists
The adsorbed component for analysis by the method of the invention may be an agonist of a receptor. The adsorbed agonist may be the naturally occurring cognate ligand of the receptor. In an alternative, the adsorbed agonist may be a non-naturally occurring ligand of the receptor. In further alternatives, the adsorbed agonist may be a peptide mimetic of the receptor or a small molecule capable of binding to the receptor. An example of a small molecule capable of binding to the receptor is a SMIP (small molecule immunopotentiator).
For example, the adsorbed component may be a TLR agonist which comprises an adsorptive moiety and a TLR agonist moiety. The adsorptive moiety confers the ability to adsorb to an insoluble metal salt (see above), whereas the TLR agonist moiety confers the ability to agonise a Toll-like receptor. Typically a TLR agonist assayed by the method of the invention would thus function as a TLR agonist even without its adsorptive moiety. Except where otherwise stated, TLR agonists can activate any of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 or TLR11.
Where the a compound is referred to as a TLR agonist, the compound is preferably an agonist of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10 or TLR11. From this group, a preferred sub-group is TLR1, TLR2, TLR3, TLR5, TLR6, TLR7, TLR8 and TLR11. A more preferred subgroup is TLR2, TLR7 and TLR8. Another preferred subgroup is TLR2 and TLR7.
Most preferably, a TLR agonist is an agonist of a human TLR.
Numerous other agonists which increase the immune response of a subject are suitable for use as adsorbed components for analysis by the method of the invention.
Pharmaceutical Compositions and Products
The method of the invention can be used to analyse components adsorbed to insoluble metal salts from a batch of adsorbed component which is then used in the manufacture of pharmaceutical compositions and products. The assayed batch of adsorbed component can be formulated in numerous ways, and the formulation can comprise many further components.
A pharmaceutical composition comprising the adsorbed component may be generated by the addition of one or more pharmaceutically acceptable excipients. A thorough discussion of such components is available in reference 40.
Pharmaceutical compositions comprising the adsorbed component are preferably in aqueous form, particularly at the point of administration, but they can also be presented in non-aqueous liquid forms or in dried forms e.g. as gelatin capsules, or as lyophilisates, etc., following analysis by a method of the present invention. Thus a method of the invention may comprise the step of lyophilising a suspension of an adsorbed component.
Pharmaceutical compositions comprising the adsorbed component may include one or more preservatives, such as thiomersal or 2-phenoxyethanol. Mercury-free compositions are preferred, and preservative-free vaccines can be prepared. Thus a method of the invention may comprise the step of adding a preservative.
Pharmaceutical compositions comprising the adsorbed component can include a physiological salt, such as a sodium salt e.g. to control tonicity. Sodium chloride (NaCl) is typical, which may be present at between 1 and 20 mg/ml e.g. 10±2 mg/ml or 9 mg/ml. Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, etc. Thus a method of the invention may comprise the step of adding a physiological salt.
Pharmaceutical compositions comprising the adsorbed component can have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, e.g. between 240-360 mOsm/kg, or between 290-310 mOsm/kg. Thus a method of the invention may comprise the step of adjusting the osmolality of the suspension of adsorbed component to between 200 mOsm/kg and 400 mOsm/kg, e.g. between 240-360 mOsm/kg, or between 290-310 mOsm/kg. Pharmaceutical compositions comprising the adsorbed component may include compounds in plain water (e.g. w.f.i.) but will usually include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (particularly with an aluminium hydroxide adjuvant); or a citrate buffer. Buffer salts will typically be included in the 5-20 mM range. Thus a method of the invention may comprise the step of adding or exchanging the buffer in a suspension of adsorbed component, for example to a phosphate buffer, a Tris buffer, a borate buffer, a succinate buffer or a histidine buffer.
Pharmaceutical compositions comprising the adsorbed component typically have a pH between 5.0 and 9.5 e.g. between 6.0 and 8.0. Thus a method of the invention may comprise the step of adjusting the pH of a suspension of adsorbed component, optionally to between 5.0 and 9.5 e.g. between 6.0 and 8.0.
Pharmaceutical compositions are preferably sterile. Thus a method of the invention may comprise the step of sterilising a suspension of adsorbed component.
Pharmaceutical compositions preferably non-pyrogenic e.g. containing <1 EU (endotoxin unit, a standard measure) per dose, and preferably <0.1 EU per dose. Thus a method of the invention may comprise the step of removing endotoxin from a suspension of adsorbed component.
Pharmaceutical compositions are preferably gluten free. Thus a method of the invention may comprise the step of removing gluten from a suspension of adsorbed component.
Pharmaceutical compositions prepared by the method of manufacture of the invention are suitable for administration to animal (and, in particular, human) patients, and thus include both human and veterinary uses. They may be used in a method of raising an immune response in a patient, comprising the step of administering the composition to the patient.
Pharmaceutical compositions may be prepared in unit dose form. In some embodiments a unit dose may have a volume of between 0.1-1.0 ml e.g. about 0.5 ml. Thus a method of the invention may comprise the step of preparing a unit dose.
Pharmaceutical compositions assayed by the methods of the invention may be prepared in various forms. For example, the compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared (e.g. a lyophilised composition or a spray-freeze dried composition). The composition may be prepared for topical administration e.g. as an ointment, cream or powder. The composition may be prepared for oral administration e.g. as a tablet or capsule, as a spray, or as a syrup (optionally flavoured). The composition may be prepared for pulmonary administration e.g. by an inhaler, using a fine powder or a spray. The composition may be prepared as a suppository or pessary. The composition may be prepared for nasal, aural or ocular administration e.g. as a spray or drops. The composition may be in kit form, designed such that a combined composition is reconstituted just prior to administration to a patient. Such kits may comprise one or more antigens in liquid form and one or more lyophilised antigens. Injectables for intramuscular administration are typical. Thus a method of the invention may comprise the step of preparing an injectable.
Compositions comprise an effective amount of one or more adjuvanted components i.e. an amount which, when administered to an individual, either in a single dose or as part of a series, is effective for enhancing the immune response. This amount can vary depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non-human primate, primate, etc.), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. The amount will fall in a relatively broad range that can be determined through routine trials. An amount of between 1-1000 m/dose can be used e.g. from 10-100 μg per dose. Thus a method of the invention may comprise the step of diluting or concentrating the adsorbed component to achieve a concentration suitable for preparing a unit dose.
General
The term “comprising” encompasses “including” as well as “consisting” e.g. a composition “comprising” X may consist exclusively of X or may include something additional e.g. X+Y.
The word “substantially” does not exclude “completely” e.g. a composition which is “substantially free” from Y may be completely free from Y. Where necessary, the word “substantially” may be omitted from the definition of the invention.
The term “about” in relation to a numerical value x is optional and means, for example, x±10%.
Unless specifically stated, a process comprising a step of mixing two or more components does not require any specific order of mixing. Thus components can be mixed in any order. Where there are three components then two components can be combined with each other, and then the combination may be combined with the third component, etc.
Where animal (and particularly bovine) materials are used in the culture of cells, they should be obtained from sources that are free from transmissible spongiform encaphalopathies (TSEs), and in particular free from bovine spongiform encephalopathy (BSE). Overall, it is preferred to culture cells in the total absence of animal-derived materials.
Where a compound is administered to the body as part of a composition then that compound may alternatively be replaced by a suitable prodrug.
The term “antibody” includes any of the various natural and artificial antibodies and antibody-derived proteins which are available, and their derivatives, e.g. including without limitation polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, single-domain antibodies, whole antibodies, antibody fragments such as F(ab′)2 and F(ab) fragments, Fv fragments (non-covalent heterodimers), single-chain antibodies such as single chain Fv molecules (scFv), minibodies, oligobodies, dimeric or trimeric antibody fragments or constructs, etc. The term “antibody” does not imply any particular origin, and includes antibodies obtained through non-conventional processes, such as phage display. Antibodies of the invention can be of any isotype (e.g. IgA, IgG, IgM i.e. an α, γ or μ heavy chain) and may have a κ or a λ light chain.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an image of an SDS-PAGE gel displaying the adsorption capacity of aluminium hydroxide for the antigen NadA. Odd numbered lanes are supernatant treated with deoxycholic acid sodium salt (DOC) and trichloroacetic acid (TCA) of aluminium hydroxide adsorbed samples at 50, 100, 200, 400, 800 and 1600 μg ml−1 of NadA. Even lanes are aluminium hydroxide pellet desorbed samples from formulation with: 50, 100, 200, 400, 800 and 1600 μg ml−1 of NadA. Each sample contained 3000 μg ml−1 aluminium hydroxide.
FIGS. 2a-2g are a series of histograms showing an increase in fluorescence detected with increasing concentrations of NadA (FIG. 2a ) 0 μg m−1 (FIG. 2b ) 50 μg ml−1 (FIG. 2c ) 100 μg ml−1 (FIG. 2d ) 200 μg ml−1 (FIG. 2e ) 400 μg ml−1 (FIG. 2f ) 800 μg ml−1 and (FIG. 2g ) 1600 μg ml−1. The left hand peak in each image represents aluminium hydroxide particles without adsorbed component. With increasing concentration, a larger proportion of particles are seen to shift to the right, indicating an elevated level of fluorescence from a label specifically attached to NadA.
FIGS. 3a-3d are a series of histograms showing the results of the tests for autoflorescence of the assay components. The histograms represent the event counts versus the fluorescence measured for the APC-A channel 660/20. (FIG. 3a ) Analysis of aluminium hydroxide by flow cytometry identifies 99% of the aggregates as having fluorescence intensity less than 1000. (FIGS. 3b, 3c, 3d ) Similar analyses of aluminium hydroxide together with assay components (NadA (b), NadA+BSA (FIG. 3c ), and NadA, BSA and anti-NadA rabbit antibody (FIG. 3d )) indicated no inherent fluorescence over the background level for the antigen NadA, the blocking agent (BSA) or by the primary antibody.
FIGS. 4a-4c are a series of histograms showing the specificity of antibody binding to NadA adsorbed to aluminium hydroxide. The histograms represent the event counts in percentage (%) versus the relative fluorescence intensity measured for the APC-Alexa 647 at channel 660/20 for various sample controls. (FIG. 4a ) Non-specific binding was determined by performing the flow cytometry assay in absence of antigen with primary antibody diluted 1:1000 and 1:1000 or containing 100 μg ml−1 NadA but using irrelevant primary antibody. (FIG. 4b ) The BSA treatment was successful in blocking the level of fluorescence for aluminium hydroxide particles (left peak) by 10-fold lower to the levels measured for the complete assay with NadA formulated at 100 μg ml−1 (right peak). (FIG. 4c ) The assay is highly reproducible, and only minor variation was observed between identical formulations assay at time 0 and 24 h apart or after waiting 24 h following the antibody staining (three overlapping peaks).
FIG. 5 is a representation of scatter plots for all standard formulations (0-300 μg ml−1). The gated dots appeared as a single uniform population of particles with increased concentration of adsorbed NadA having no impact on forward and side scatter measurements.
FIGS. 6a-6g are a series of scatter plots forming an analysis of the antigen distribution of NadA on aluminium hydroxide aggregates using side scattering and relative fluorescence intensity (RFI). The percentage of florescent particles increases with the concentration of NadA (0, 9.375, 18.75, 37.5, 75, 150, 300 μgml−1). FIG. 6a shows the percentage of fluorescent particles at a concentration of 0 μg/ml−1 NadA. FIG. 6b shows the percentage of fluorescent particles at a concentration of 9.375 μg/ml−1 NadA. FIG. 6c shows the percentage of fluorescent particles at a concentration of 18.75 μg/ml−1 NadA. FIG. 6d shows the percentage of fluorescent particles at a concentration of 37.5 μg/ml−1 NadA. FIG. 6e shows the percentage of fluorescent particles at a concentration of 75 μg/ml−1 NadA. FIG. 6f shows the percentage of fluorescent particles at a concentration of 150 μg/ml−1 NadA. FIG. 6g shows the percentage of fluorescent particles at a concentration of 300 μg/ml−1 NadA.
FIG. 7 is a graph of a standard curve of NadA concentration in the flow cytometry assay calculated with three-parameter non-linear regression analysis (y=ax3+bx2+cx) with correlation coefficients R2>0.99. The y axis displays the percentage of particles with relative fluorescence intensity>1000. Each value represents the mean and standard deviations of triplicate samples performed on three independent experiments. Results showed the detection of the MenB antigen NadA in the range of 3.12-100 μg/dose (6.24-200 μg ml−1).
FIG. 8 is a graph showing the excitation profile of a number of SMIPs.
FIGS. 9a-9d are a series of scatter plots providing a morphological analysis of aluminium hydroxide-Compound C formulation and controls based on forward and side scatter parameters (FSC and SSC). (FIG. 9a ) Aluminium hydroxide, (FIG. 9b ) Compound C (FIG. 9c ) Filtered compound C and (FIG. 9d ) Compound C adsorbed to aluminium hydroxide.
FIGS. 10a-10c are a series of scatter plots providing a morphological analysis of aluminium hydroxide +Compound A formulation and relative controls based on forward and side scatter parameters (FSC and SSC). (FIG. 10a ) Aluminium hydroxide, (FIG. 10b ) Compound A, (FIG. 10c ) Compound A with aluminium hydroxide.
FIGS. 11a-11n show a series of histograms showing the shift of the positive fluorescence peak detected with labeled secondary antibody 961c specific. The shift to the right is directly proportional to amount of 961c adsorbed onto aluminum hydroxide particles adsorbed with 961c only (FIGS. 11a-11g ), and when this component was adsorbed as part of a 3-component combination (FIGS. 11h-11n ). (FIGS. 11a, 11h ) 0 μg ml−1, (FIGS. 11b, 11i ) 50 μg ml−1, (FIGS. 11c, 11j ) 100 μg ml−1, (FIGS. 11d, 11k ) 150 μg ml−1, (FIGS. 11e , 11 −1) 200 μg ml−1, (FIGS. 11f, 11m ) 250 μg ml−1, (FIGS. 11g ,) 400 μg ml−1, and (FIGS. 11n ) 300 μg ml−1.
FIGS. 12a-12c are a series of histograms showing fluorescence traces for aluminium hydroxide formulations for (FIG. 12a ) Compound B and (FIG. 12b ) Compound C. The histograms show increased fluorescence intensity of SMIP-aluminium hydroxide particles (both in the presence and absence of an antigen) with respect to negative controls. This increase is irrespective of whether or not the aluminium hydroxide also has a protein component adsorbed to it. Aluminium hydroxide mixed with Compound A (FIG. 12c ), on the contrary, does not show fluorescence as Compound A does not adsorb on aluminium hydroxide particles.
FIG. 13a is a histogram which shows that prior to adsorption and following desorption of SMIP Compound B, aluminium hydroxide particles do not fluoresce in the same manner as when Compound B is adsorbed and FIG. 13b is a histogram which shows that prior to adsorption and following desorption of SMIP Compound C, aluminium hydroxide particles do not fluoresce in the same manner as when Compound C is adsorbed.
FIG. 14 is a graph showing the excitation profile of two further SMIPs.
FIGS. 15a-15d are a series of scatter plots providing a morphological analysis of aluminium hydroxide-Compound E formulation and controls based on forward and side scatter parameters (FSC and SSC) and a series of histograms showing fluorescence traces for aluminium hydroxide formulations for Compound E. (FIG. 15a ) PBS/PBS, (FIG. 15b ) 153/153, (FIG. 15c ) PBS/Alum, (FIG. 15d ) Alum LHD153/Alum LHD153.
 MODES FOR CARRYING OUT THE INVENTION
Further information for implementing the invention can be obtained from reference 41.
Flow Cytometry Analysis of Adsorbed Protein
Materials
Clinical grade material (GMP) of a recombinant protein antigen of Neisseria meningitidis serogroup B (MenB) NadA was used for the experiments. Anti-NadA polyclonal rabbit antibody was used as primary antibody at 1:500, dilution in 10 mM histidine buffer, pH 6.5. Alexa Fluor 647 F(ab′)2 fragment of goat anti-rabbit antibody was purchased from Molecular Probes and used at 1:800 dilution in 1×PBS. This antibody was utilized as the final step of the assay.
Preparation of Standards and Samples Formulations
A set of standard suspensions containing the antigen NadA at 300 μg ml−1 and five serial two-fold dilutions was prepared by serially diluting a stock suspension sample the day before the assay.
The stock suspension was prepared by mixing 1500 μg of aluminium hydroxide per 150 μg of NadA in 10 mM histidine buffer (pH 6.5). The final osmolarity of the formulation was adjusted to 300 mOsm/L using a 2M NaCl solution. The concentration of aluminium hydroxide in the stock solution was 3000 μg ml−1 and the concentration of NadA was 300 μg ml−1. The antigen was adsorbed by stirring the stock suspension for at least two hours at 4° C. Subsequently, the stock suspension was serially diluted, to 9.38 μg ml−1, by mixing 1 ml aluminium hydroxide-antigen suspension with 1 ml of aluminium hydroxide suspension, which had been previously adjusted for concentration, pH and osmolarity. The samples were used for assaying after an overnight incubation under rocking motion at 4° C. For each assay, blank samples containing 3000 μg ml−1 of aluminium hydroxide, adjusted to pH and osmolarity, were included as part of the standard set. In parallel, six check standard samples containing 6.25, 12.5, 25, 50 100 and 200 μg ml−1 of antigen, were prepared independently by an individual dilution from another stock suspension sample of 3000 μg ml−1 of aluminium hydroxide with 300 μg ml−1 of NadA prepared exactly as previously described. The dose volume and the aluminium hydroxide concentration for each standard and check sample were respectively 500 μl and 1500 μg/dose (human dose).
The aluminium hydroxide binding capacity (3000 μg ml−1 in 10 mM histidine pH 6.5, 300 mOsm/L) was evaluated for several formulations of NadA at 50, 100, 200, 400, 800 and 1600 ml−1. To determine antigen adsorption, each formulation was centrifuged at 3000 g for 20 minutes and the supernatant was removed without disturbing the pellet. To precipitate the possible unbound antigens, the supernatants were treated with 0.5% deoxycholic acid sodium salt (DOC), incubated for 10 min at room temperature, followed by the addition of 60% trichloroacetic acid (TCA). The TCA pellets were re-suspended with sample buffer while the aluminium pellets were re-constituted with sample buffer containing 0.5 M Sodium phosphate at pH 8. Samples were loaded into a NUPAGE Novex 4-12% gradient Bis-Tris Midi gel and run under reducing conditions at a constant voltage of 200 V for approximately 50 minutes. The gels were stained-destained with colloidal blue staining kit.
At the clinical dose of 50 μg (100 μg ml−1), NadA antigen is predominantly adsorbed to the aluminium hydroxide adjuvant. Any unabsorbed antigen in the formulation supernatant was below the limit of detection (<2%; FIG. 1). Furthermore, unabsorbed NadA in the formulation supernatant was not detectable at an antigen concentration of 800 μg/ml indicating ≧98% adsorption at this antigen concentration. Antigen was, however, detectable at 1600 μg/ml indicating that the adsorptive capacity of 1500 μg of aluminium hydroxide for NadA lies somewhere between 800 and 1600 μg/ml of NadA, and that at the clinical dose of 50 μg the amount of NadA adsorbed is significantly below the adsorptive capacity limit of the adjuvant of 1500 μg per dose in 10 mM histidine pH 6.5.
Flow Cytometry Assay
The assay utilized to analyse the NadA adsorbed to insoluble aluminium hydroxide was a three-step procedure: the saturation of the free sites on the aluminium hydroxide, the primary binding with an antibody that specifically recognizes the antigen NadA and the staining with a fluorescently labelled secondary antibody that binds to the first antibody.
First the BSA was added to the adsorbed component composition, followed by a 30 minute incubation at 4° C. using a vertical rotary mixer. After this step primary antibody was added, and followed by a further 30 minute incubation at 4° C. using a vertical rotary mixer. The secondary antibody was added followed by incubation for 20 minutes at room temperature without mixing, in the dark. The blank, standard and check samples were placed on 96-microwell polypropylene plates. The 75 μl/well suspensions were saturated with 25 μl of 10% BSA in 10 mM histidine buffer pH 6.5. After the incubation, plates were centrifuged (3000 g for 5 minutes) and the supernatants were removed. The aluminium pellets were then washed and centrifuged twice with 100 μl of 10 mM histidine buffer pH 6.5. To reduce the background, the primary antibody, rabbit anti-NadA, was pre-adsorbed with a goat serum (diluted 1/10 in histidine buffer pH 6.5) and subsequently diluted up to 1/500 in histidine buffer pH 6.5. The washed pellets were resuspended with 75 μl of histidine buffer pH 6.5 and 75 μl of primary antibody was subsequently added. Then, the samples were incubated and washed-centrifuged as previously described. Goat anti-rabbit antibody, Alexa Fluor 647® fluorescently labelled, was diluted 1/800 in PBS 1× and then added to each well. After the incubation, plates were washed and centrifuged and resuspended in 1×PBS. The treated samples were read and acquired on a FACSCanto™ II using filter for APC-A channel (660/20 nm).
Auto Fluorescence of Assay Components
Analysis of aluminium hydroxide by flow cytometry identifies 99% of the aggregates having fluorescence intensity less than 1000. Similar analysis of aluminium hydroxide together with assay components indicated no inherent fluorescence over this background level for the antigen NadA, the BSA used as a blocking agent and the primary antibodies (FIGS. 2a-2g ).
Effect of Assay Buffer Systems on Antigen Adsorption
Adsorption of antigens to aluminium hydroxide adjuvants depends on pH, ionic strength and the presence of anions such as phosphate (reference 42). Therefore, it was necessary to evaluate the influence of the assay conditions on NadA adsorption.
The amount of antigen that is released from aluminium hydroxide during each of the blocking, staining and washing was measured in the supernatant of the assay sample after each of these steps (data not shown). Eluted antigen was not detectable in the supernatant until the incubation with the secondary antibody and the final washing step with PBS. Some antigen was displaced from aluminium hydroxide during the final wash with PBS. These were found to be in the range of 5% to 10% of antigen present in the formulation. Substitution of PBS with histidine buffer for this final wash was able to alleviate this effect with no detectable antigen released into the wash buffer (data not shown). The antigen loss following exchange to a PBS buffer was not found to have a significant effect of the predictive capability of the assay to determine, reliably and accurately, the concentration of antigen bound to the insoluble metal salt (see Table 3).
Furthermore, despite these observations, the antigen remained predominantly bound to aluminium hydroxide with recovery of the majority of the antigen from aluminium hydroxide once antibody staining procedure had been completed.
Specificity of Antibody Binding Against Adsorbed Antigen to Aluminium
Analysis of the fluorescence intensity of the standard formulation confirmed that for the aluminium hydroxide at 3000 μg ml−1 containing no of NadA, most of the adjuvant aggregates (>99%) had fluorescence intensity less than 1000 (FIG. 3b ). While at the NadA concentration of 100 μg ml−1 (human dose), the aggregates had a marked increase in relative fluorescence with a mean relative fluorescence 9.6 fold greater than that observed for the no NadA formulation. As antibodies have been reported to adsorb to aluminium hydroxide adjuvant via ligand exchange and electrostatic interactions, it was necessary to investigate whether there is any unspecific binding of the primary and secondary antibodies to aluminium hydroxide in the formulation.
To counter any non-specific binding, aluminium hydroxide was blocked with 2.5% BSA prior to staining with the primary and secondary antibodies. This blocking was successful in limiting non-specific binding, as performing the flow cytometry assay in the absence of antigen with primary antibodies diluted 1:1000 and 1:10000 resulted in levels of fluorescence for the aluminium hydroxide particles 10-fold below levels observed for the complete assay with NadA formulated at 100 μg ml−1 (FIG. 3a ). Furthermore when the assay was performed with irrelevant primary antibodies not specific for NadA, the levels of fluorescence remained equal to those observed in the absence of antigen, indicating that unspecific binding between NadA and the fluorescently labelled secondary antibody is not significant (FIG. 3a ).
To evaluate the stability and reproducibility of the assay, multiple formulations were prepared in parallel but stained and/or analyzed by flow cytometry at different time intervals (FIG. 3c ). These data indicate that the assay is highly reproducible because little variation was observed between identical formulations assayed 24 hours apart. Furthermore the assay is stable because waiting 24 hours following the antibody staining procedure of the assay had little impact on the levels of fluorescence measured by flow cytometry analysis.
Morphology and Antigen Distribution of Standard Formulations
Standard formulations, prepared from a stock solution of 300 μg ml−1 for NadA and serially 2-fold diluted five times with aluminium hydroxide suspension, were analyzed by flow cytometry using both forward (FSC) and side scatter (SSC), parameters associated with particle size and morphology respectively. All standard formulations appeared as a single uniform population of particles (FIGS. 4a-4c ), with increased concentration of adsorbed NadA having no impact on forward and side scatter measurements. Antigen distribution of NadA on aluminium hydroxide aggregates was analyzed using SSC and relative fluorescence intensity (RFI). The analysis of the RFI revealed that when the suspension had no antigen adsorbed, 99% of the aggregates showed an RFI<1000. However, as the concentration of NadA gradually increased, the fluorescence intensity increased proportionally to the amount of antigen adsorbed (FIG. 5). When aluminium hydroxide particles are loaded with the highest concentration (300 μg ml−1) the entire suspension exposed a uniformed fluorescence 23-fold higher than the aluminium hydroxide alone.
Direct Quantification of Adsorbed NadA Antigen in Vaccine Formulation
Standard formulations were prepared in the range of 0-100 μg ml−1 and tested by the flow cytometry assay. Standard curves generated by three-parameter non-linear regression analysis had correlation coefficients R2>0.99 (FIGS. 6a-6g ). To evaluate the reliability of the standard curves for measuring antigen concentrations, a series of test samples in the same concentration range were assayed and their protein concentration determined from fluorescence readings (Table 3). The results showed that the flow cytometry assay is accurate and reliable with overall percent accuracy of the test formulations in the range of 85% or greater.
Factorial In Vitro Displacement Study
An in vitro displacement study was performed to determine whether the protein BSA, used as the blocking agent, or the primary or secondary antibodies interfere with antigen adsorbed by displacing it from aluminium hydroxide during the assay. The experiment was done in U96-microwell polypropylene plates. Aliquots of 75 μl of a clinical dose sample were mixed with BSA blocking solution, followed by the primary and secondary antibodies. The addition of each reagent was followed by 30 minutes incubation at 4° C., 20 minutes for the secondary antibody, followed by washing steps. After each incubation, the supernatant was kept for further analysis. The presence of the MenB protein in the supernatants was evaluated by SDS-PAGE and the protein was evidenced by western blotting using the same polyclonal antibody used for the assay.
Analysis of Suspensions with More than One Adsorbed Component
Another advantage common to antibody based assays specific for a target antigen is the potential of the assay to be applied directly to complex formulations containing multiple antigens and adjuvants such as combination vaccines. The assay was applied to a trivalent vaccine containing GNA2091-1870 and GNA2132-1030 in addition to NadA, and found no interference of these antigens in determining adsorbed concentrations of NadA.
Discussion
In addition to the accuracy, sensitivity and reproducibility of the flow cytometry assay possesses a number of other key advantages which stem from the fact that as flow cytometry analyses physical particles it is measuring the antigen directly on the surface of the aluminium particles. Firstly the degree of antigen adsorption to aluminium hydroxide is measured directly without the reliance on indirect measurements of unadsorbed antigen in formulation supernatants. Secondly, as the assay may be antibody based, it is possible for flow cytometry to be used to monitor antigen stability whilst still bound to the surface of insoluble metal salt adjuvants. This could be particularly powerful for antigens where protective epitopes have been well defined and in which monoclonal antibodies specific for these regions could be used in the flow cytometry assay to monitor structural integrity of the epitopes over time or to monitor vaccine consistency prior to release. Finally another potential advantage of this assay is that it is able to determine protein concentrations on each insoluble metal salt particle which can reveal the uniformity of antigen distribution in the formulation. With guidelines in the literature (e.g. reference 43) describing different adsorption strategies for the production of multi-component vaccines, flow cytometry based assays could help monitor uniformity of resulting vaccines and importance of antigen distribution on efficacy.
Flow Cytometry Analysis of Adsorbed Small Molecules
Flow cytometry (FC) based technology can be used for the direct detection of SMIPs on aluminium hydroxide with no need for labelling. The assay was tested using a new class of TLR7 agonists which are analogs of the lead compound Compound A. Benzonaphthyridine is the core scaffold of the series and the molecules have intrinsic fluorescence features. Association of SMIPs with aluminium hydroxide transforms plain insoluble metal salt particles into particles that display fluorescent tags, detectable with flow cytometry by combining the light scattering properties with the intensity of fluorescence upon appropriate excitation.
Fluorescence spectroscopy confirmed that Compound A, Compound C, Compound B, Compound E and Compound H can be excited in the violet visible spectrum and emit fluorescence in the blue/green visible spectrum with slight differences in wavelength (FIGS. 8 and 14).
Aluminium hydroxide based formulations were analyzed on the FACS Canto II system and characterized by associated morphological parameters (FSC and SSC). Negative controls included aluminium hydroxide alone, small molecule solutions, PBS and Alum-3 MenB vaccine (FIGS. 9a-9d shows the results of these experiments for Compound C).
Aluminium hydroxide alone was gated to cover a homogeneous and compact population, which was based on screening tens of thousands of event to determine light scatter of light emitted by 488 nm blue laser source. Analysis of a solution of Compound C and the PBS control resulted in no detection of particles through light scattering over the background instrumental noise. The gate covered most of the particles of alum (more than 90%) and was applied to all other samples and used to evaluate fluorescence intensity. Filtration of SMIP solutions helped to avoid scatter of precipitated particles or co-precipitation of SMIPs and aluminium hydroxide when formulated together. Aluminium hydroxide alone was gated to cover an homogeneous and compact population (FIG. 10a ). The gate was applied to Compound A and no overlapping of light scatter could be found (FIG. 10b ). When mixed together they still behave as two different populations (FIG. 10c ), in contrast to the single homogenous population observed when Compound C was adsorbed to aluminium hydroxide. Compound E also adsorbed to aluminium hydroxide and behaved as a single population (FIGS. 15a-15d ).
Aluminium hydroxide particles included in the applied gate were analyzed for their fluorescence intensity at FACS Canto II using violet laser (405 nm) as excitation source and two different filters for emission: 525/50 nm and 450/50 nm (FIGS. 10a-10c ).
A desorption protocol was used to further confirm binding of SMIPs to aluminium hydroxide. SMIP-aluminium hydroxide formulation was treated with a 0.5M phosphate buffer (pH9) and the desorbed aluminium hydroxide was washed with either water (for soluble compounds) or butanol (for poorly water soluble compounds). The aluminium hydroxide was then analyzed again on FACS Canto II, using the same instrument settings, and showed no fluorescence like aluminium hydroxide alone (FIGS. 11a-11n ).
The fluorescence properties of TLR7 SMIPs have been fully exploited to develop a novel assay for the direct detection of SMIPs on aluminium hydroxide. Flow cytometry proved to be a unique tool for the qualitative characterization of SMIP-aluminium hydroxide formulations even in the presence of antigens (see FIGS. 12a & 12 b). The adsorption of SMIPs on aluminium hydroxide is well supported by the observation that SMIP-aluminium hydroxide particles have fluorescent features respect to negative control, the light scatter of soluble SMIPs was negligible, the light scatter of insoluble SMIPs (Compound A, not adsorbed on aluminium hydroxide) had different morphology, aluminium hydroxide returns to its negative fluorescence status upon desorption of SMIP. Fluorescence properties were also used to confirm association of SMIPs on aluminium hydroxide via confocal microscopy.
The fluorescence of SMIP can be further exploited to evaluate in vitro SMIP uptake by macrophages via flow cytometry as a powerful tool to understand localization of SMIPs in cells and understand the effect of aluminium hydroxide formulations on the internalization of TLR agonists. Preliminary analyses showed that this type of assay is feasible.
It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.
TABLE 1
Commonly used fluorescent labels
Absorbance Emission
Dye Wavelength Wavelength Visible colour
Hydroxycoumarin 325 386 blue
methoxycoumarin 360 410 blue
Alexa fluor 345 442 blue
aminocoumarin 350 445 blue
Cy2 490 510 green (dark)
FAM 495 516 green (dark)
Alexa fluor 488 494 517 green (light)
Fluorescein FITC 495 518 green (light)
Alexa fluor 430 430 545 green (light)
Alexa fluor 532 530 555 green (light)
HEX 535 556 green (light)
Cy3 550 570 yellow
TRITC 547 572 yellow
Alexa fluor 546 556 573 yellow
Alexa fluor 555 556 573 yellow
R-phycoerythrin (PE) 480; 565 578 yellow
Rhodamine Red-X 560 580 orange
Tamara 565 580 red
Cy3.5 581 581 596 red
Rox 575 602 red
Alexa fluor 568 578 603 red
Red 613 480; 565 613 red
Texas Red 615 615 red
Alexa fluor 594 590 617 red
Alexa fluor 633 621 639 red
Allophycocyanin 650 660 red
Alexa fluor 633 650 668 red
Cy5 650 670 red
Alexa fluor 660 663 690 red
Cy5.5 675 694 red
TruRed 490; 675 695 red
Alexa fluor
680 679 702 red
Cy7 743 770 red
TABLE 2
TLR Agonists
TLR7 agonist Structure
Compound A
Figure US09618508-20170411-C00001
Compound B
Figure US09618508-20170411-C00002
Compound C
Figure US09618508-20170411-C00003
Compound D
Figure US09618508-20170411-C00004
Compound E
Figure US09618508-20170411-C00005
Figure US09618508-20170411-C00006
Compound F
Figure US09618508-20170411-C00007
Figure US09618508-20170411-C00008
Compound G
Figure US09618508-20170411-C00009
Figure US09618508-20170411-C00010
Compound H
Figure US09618508-20170411-C00011
Figure US09618508-20170411-C00012
TABLE 3
Comparison of nominal concentration and concentration
detected by the flow cytometry assay
Nominal Concentration
concentrationa detectedb Accuracyc CVd
(μg/500 μl) (μg/500 μl) (%) (%)
3.12  3.01 +/− 0.1 94.8 +/− 2.1 4.8
6.25  6.27 +/− 0.3 96.4 +/− 2.8 4.8
12.5 12.79 +/− 0.2 97.6 +/− 1.6 1.6
25 24.87 +/− 0.8 97.5 +/− 2.0 3.4
50  50.5 +/− 2.8 94.8 +/− 1.5 5.7
100 113.98 +/− 12.3  84.7 +/− 10.1 10.8
aTest samples of NadA on Aluminium hydroxide were freshly formulated and diluted to a final concentration with Aluminium hydroxide suspension (3.0 mg/ml)
bBack calculation was performed by converting the percentage of fluorescence reading of the standard concentrations of antigen using three-parameter non-linear regression analysis.
c% accuracy is percent similarity between the amount of NadA calculated by back calculation (detected by flow cytometry assay) and the known amount of NadA
dCV, coefficient of variation between assays, CV is calculated as standard deviation divided by the mean
REFERENCES
  • [1] WO2004/038417.
  • [2] Thiele et al. (1990) J Clin Lab Anal 4:126-9.
  • [3] Lai et al. (2008) Applied Spectroscopy 62:784-90.
  • [4] Zhu et al. (2009) J Immunol Methods 344:73-8.
  • [5] The Molecular Probes® Handbook—A Guide to Fluorescent Probes and Labeling Technologies (11th Ed.; lnvitrogen)
  • [6] International patent application PCT/IB2010/002386.
  • [7] Vaccine Design . . . (1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.
  • [8] Treanor et al. (1996) J Infect Dis 173:1467-70.
  • [9] Keitel et al (1996) Clin Diagn Lab Immunol 3:507-10.
  • [10] WO03/097091.
  • [11] Cassone & Torosantucci (2006) Expert Rev Vaccines 5:859-67.
  • [12] PCT/IB2010/052445.
  • [13] PCT/IB2010/000998.
  • [14] Giuliani et al. (2006) Proc Natl Acad Sci USA. 103:10834-9.
  • [15] WO95/27787.
  • [16] WO03/010317.
  • [17] WO2007/110700.
  • [18] WO2006/138004.
  • [19] WO2005/084306.
  • [20] WO2005/002619.
  • [21] WO03/049762.
  • [22] WO02/02606.
  • [23] WO00/37494.
  • [24] WO2008/020330.
  • [25] WO2006/091517.
  • [26] WO2006/089264.
  • [27] Covacci & Rappuoli (2000) J. Exp. Med. 19:587-592.
  • [28] WO 93/18150.
  • [29] Covacci et al. (1993) Proc. Natl. Acad. Sci. USA 90:5791-5795.
  • [30] Tummuru et al. (1994) Infect. Immun. 61:1799-1809.
  • [31] Marchetti et al. (1998) Vaccine 16:33-37.
  • [32] Telford et al. (1994) J. Exp. Med. 179:1653-1658.
  • [33] Evans et al. (1995) Gene 153:123-127.
  • [34] WO 96/01272 & WO96/01273, especially SEQ ID NO:6.
  • [35] WO 97/25429.
  • [36] MMWR Morb Mortal Wkly Rep 1998 Jan. 16; 47(1):12, 19.
  • [37] Harper et al. (2004) Lancet 364(9447):1757-65.
  • [38] U.S. Pat. No. 6,699,474.
  • [39] WO2007/060548.
  • [40] Remington: The Science and Practice of Pharmacy (Gennaro, 2000; 20th edition, ISBN: 0683306472).
  • [41] Ugozzoli et al. (2011) Analytical Biochemistry 418:224-230.
  • [42] Hem and HogenEsch (2007) Expert Rev Vaccines 6:685-698.
  • [43] Matheis et al. (2001) Vaccine 20:67-73.

Claims (20)

The invention claimed is:
1. A flow cytometric method for measuring the amount of a component adsorbed to an insoluble metal salt, wherein the measuring comprises the steps of: (i) labelling the adsorbed component with a labelled binding reagent to produce a labelled component; and (ii) measuring the amount of the labelled adsorbed component on the insoluble metal salt particles by flow cytometry.
2. The method according to claim 1 further comprising, before analysis, the step of adsorbing the component to the insoluble metal salt.
3. The method according to claim 1, wherein the labelling step is preceded by a blocking step.
4. The method according to claim 1, wherein the component is a polypeptide antigen.
5. The method according to claim 1, wherein the component is an immunopotentiator.
6. The method according to claim 1, wherein the metal salt is an aluminium salt.
7. The method according to claim 6, wherein the aluminium salt comprises an aluminium hydroxide and/or an aluminium phosphate.
8. The method according to claim 1, wherein the labelled binding reagent comprises an antibody.
9. The method according to claim 8, wherein the labelled binding reagent comprises a primary antibody and a secondary antibody.
10. The method according to claim 1, wherein the labelled binding reagent comprises a fluorophore.
11. A method for analysing the distribution of a component which is adsorbed to an insoluble metal salt particles, comprising steps of: (i) labelling the adsorbed component with a labelled binding reagent to produce a labelled adsorbed component; and (ii) analysing the distribution of the labelled adsorbed component on the insoluble metal salt particles by flow cytometry.
12. The method according to claim 11 further comprising, before analysis, the step of adsorbing the component to the insoluble metal salt particles.
13. The method according to claim 11, wherein the labelling step is preceded by a blocking step.
14. The method according to claim 11, wherein the component is a polypeptide antigen.
15. The method according to claim 11, wherein the component is an immunopotentiator.
16. The method according to claim 11, wherein the metal salt particles are aluminium metal salt particles.
17. The method according to claim 16, wherein the aluminium metal salt particles comprises aluminium hydroxide particles and/or an aluminium phosphate particles.
18. The method according to claim 17, wherein the labelled binding reagent comprises antibody.
19. The method according to claim 18, wherein the labelled binding reagent comprises a primary antibody and a secondary antibody.
20. The method according to claim 11, wherein the labelled binding reagent comprises a fluorophore.
US13/994,536 2010-12-14 2011-12-14 Flow cytometry analysis of materials adsorbed to metal salts Active US9618508B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/994,536 US9618508B2 (en) 2010-12-14 2011-12-14 Flow cytometry analysis of materials adsorbed to metal salts

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42300110P 2010-12-14 2010-12-14
US13/994,536 US9618508B2 (en) 2010-12-14 2011-12-14 Flow cytometry analysis of materials adsorbed to metal salts
PCT/US2011/064938 WO2012082914A1 (en) 2010-12-14 2011-12-14 Flow cytometry analysis of materials adsorbed to metal salts

Publications (2)

Publication Number Publication Date
US20130330840A1 US20130330840A1 (en) 2013-12-12
US9618508B2 true US9618508B2 (en) 2017-04-11

Family

ID=45444741

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/994,536 Active US9618508B2 (en) 2010-12-14 2011-12-14 Flow cytometry analysis of materials adsorbed to metal salts

Country Status (4)

Country Link
US (1) US9618508B2 (en)
EP (1) EP2652511B8 (en)
ES (1) ES2630029T3 (en)
WO (1) WO2012082914A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
US9315530B2 (en) 2010-09-01 2016-04-19 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
ES2681698T3 (en) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Combination vaccines with lower doses of antigen and / or adjuvant
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
JP7413271B2 (en) * 2018-03-20 2024-01-15 サノフィ パスツ－ル リミテッド How to determine adjuvanted protein concentration and percent adsorption using intrinsic fluorescence
US12196652B2 (en) 2018-08-01 2025-01-14 Sartorius Bioanalytical Instruments, Inc. Methods, kits and stain compositions for flow cytometry evaluation of unassociated virus-size particles using multiple fluorogenic dyes
US11709116B2 (en) 2020-02-04 2023-07-25 Sartorius Bioanalytical Instruments, Inc. Liquid flourescent dye concentrate for flow cytometry evaluation of virus-size particles and related products and methods
US20230010633A1 (en) * 2021-07-10 2023-01-12 Peter J. Wilk Dna location method and apparatus

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018150A1 (en) 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
WO1995027787A1 (en) 1994-04-06 1995-10-19 Pierre Fabre Medicament Peptide fragment of the respiratory syncytial virus g protein, immunogenic agent, pharmaceutical composition containing same, and preparation method
WO1996001273A1 (en) 1994-07-01 1996-01-18 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
WO2000037494A2 (en) 1998-12-18 2000-06-29 Chiron S.P.A. Chlamydia trachomatis antigens
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
WO2003010317A1 (en) 2001-07-20 2003-02-06 Pierre Fabre Medicament Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine
WO2003049762A2 (en) 2001-12-12 2003-06-19 Chiron Srl. Immunisation against chlamydia trachomatis
WO2003097091A2 (en) 2002-05-15 2003-11-27 Luciano Polonelli Glucan-based vaccines
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
WO2004038417A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals Sa Method and kit for detecting antigens
WO2005002619A2 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
WO2005022157A1 (en) 2003-08-05 2005-03-10 Alk Abello A/S Evaluation of adjuvanted vaccines
WO2005084306A2 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
WO2006091517A2 (en) 2005-02-18 2006-08-31 Novartis Vaccines And Diagnostics Inc. Immunogens from uropathogenic escherichia coli
WO2006138004A2 (en) 2005-05-12 2006-12-28 Novartis Vaccines And Diagnostics, Inc. Immunogenic compositions for chlamydia trachomatis
WO2007060548A2 (en) 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2007110700A2 (en) 2005-12-22 2007-10-04 Novartis Vaccines And Diagnostics, Srl. Chlamydial antigens
WO2007122373A1 (en) 2006-04-13 2007-11-01 Avecia Biologics Limited Method for assaying antigens
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
WO2010119343A2 (en) 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2010140119A1 (en) 2009-06-01 2010-12-09 Novartis Ag COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
WO1993018150A1 (en) 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
WO1995027787A1 (en) 1994-04-06 1995-10-19 Pierre Fabre Medicament Peptide fragment of the respiratory syncytial virus g protein, immunogenic agent, pharmaceutical composition containing same, and preparation method
WO1996001273A1 (en) 1994-07-01 1996-01-18 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
WO1996001272A1 (en) 1994-07-01 1996-01-18 Rican Limited Helicobacter proteins and vaccines
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
WO2000037494A2 (en) 1998-12-18 2000-06-29 Chiron S.P.A. Chlamydia trachomatis antigens
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
WO2003010317A1 (en) 2001-07-20 2003-02-06 Pierre Fabre Medicament Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine
WO2003049762A2 (en) 2001-12-12 2003-06-19 Chiron Srl. Immunisation against chlamydia trachomatis
WO2003097091A2 (en) 2002-05-15 2003-11-27 Luciano Polonelli Glucan-based vaccines
WO2004038417A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals Sa Method and kit for detecting antigens
WO2005002619A2 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
WO2005022157A1 (en) 2003-08-05 2005-03-10 Alk Abello A/S Evaluation of adjuvanted vaccines
EP1649287B1 (en) 2003-08-05 2008-08-06 ALK-Abelló A/S Evaluation of adjuvanted vaccines
WO2005084306A2 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
WO2006091517A2 (en) 2005-02-18 2006-08-31 Novartis Vaccines And Diagnostics Inc. Immunogens from uropathogenic escherichia coli
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
WO2006138004A2 (en) 2005-05-12 2006-12-28 Novartis Vaccines And Diagnostics, Inc. Immunogenic compositions for chlamydia trachomatis
WO2007060548A2 (en) 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2007110700A2 (en) 2005-12-22 2007-10-04 Novartis Vaccines And Diagnostics, Srl. Chlamydial antigens
WO2007122373A1 (en) 2006-04-13 2007-11-01 Avecia Biologics Limited Method for assaying antigens
US20090317919A1 (en) * 2006-04-13 2009-12-24 Allan Watkinson Method for Assaying Antigens
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
WO2010119343A2 (en) 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2010140119A1 (en) 2009-06-01 2010-12-09 Novartis Ag COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
Bernd (2009). "In Deutschland zugelassene Impfstoffe mit Aluminium-Adjuvans", Acta Crystallographica Section A, pp. 14-15, Retrieved Apr. 4, 2016 from <http://www.bermibs.de/fileadmin/pdf/impfen-sinn-oder-unsinn/impfstoffe-mit-aluminium-adjuvans.pdf>.
Bernd (2009). "In Deutschland zugelassene Impfstoffe mit Aluminium-Adjuvans", Acta Crystallographica Section A, pp. 14-15, Retrieved Apr. 4, 2016 from <http://www.bermibs.de/fileadmin/pdf/impfen-sinn—oder—unsinn/impfstoffe—mit—aluminium-adjuvans.pdf>.
Cassone et al., "Opportunistic Fungi and Fungal Infections: the Challenge of a Single, General Antifungal Vaccine," Expert Rev. Vaccines, 2006, vol. 5, No. 6, pp. 859-867.
Covacci et al., "Molecular Characterization of the 128-kDa Immunodominant Antigen of Helicobacter pylori Associated with Cytotoxicity and Duodenal Ulcer," Proc. Natl. Acad. Sci. USA, 1993, vol. 90, pp. 5791-5795.
Covacci et al., "Tyrosine-Phosphorylated Bacterial Proteins: Trojan Horses for the Host Cell," J. Exp. Med., 2000, vol. 191, No. 4, pp. 587-592.
Evans et al., "Identification of Four New Prokaryotic Bacterioferritins, from Helicobacter pylori, Anabaena variabilis, Bacillus subtilis and Treponema pallidum, by Analysis of Gene Sequences," Gene, 1995, vol. 153, pp. 123-127.
Giuliani et al., "A Universal Vaccine for Serogroup B Meningococcus," Proc. Natl. Acad. Sci. USA, 2006, vol. 103, No. 29, pp. 10834-10839.
Harper et al. "Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection with Human Papillomavirus Types 16 and 18 in Young Women: a Randomised Controlled Trial," The Lancet, 2004, vol. 364, pp. 1757-1765.
Hem et al., "Relationship between Physical and Chemical Properties of Aluminum-Containing Adjuvants and Immunopotentiation," Expert Rev. Vaccines, 2007, vol. 6, No. 5, pp. 685-698.
Katz, J.B. et al., "In Vitro Assessment of Viral Antigen Content in Inactivated Aluminum Hydroxide Adjuvanted Vaccines", J. Virol. Methiods, 25(1): 101-108 (1989).
Keitel et al., "Increasing Doses of Purified Influenza Virus Hemagglutinin and Subvirion Vaccines Enhance Antibody Responses in the Elderly," Clin. Diagn. Lab. Immunol., 1996, vol. 3, No. 5, pp. 507-510.
Lai, X. et al., "Determination of Adsorbed Protein Concentration in Aluminum Hydroxide Suspensions by Near-Infrared Transmittance Spectroscopy", Applied Spectroscopy, 62(7): 784-790 (2008).
Maraskovsky et al. (2004). "NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors," Clin Cancer Res. 10(8):2879-90.
Marchetti et al., "Protection against Helicobacter pylori Infection in Mice by Intragastric Vaccination with H. pylori Antigents is Achieved Using a Non-Toxic Mutant of E. coli Heat-Labile Enterotoxin (LT) as Adjuvant," Vaccine, 1998, vol. 16, No. 1, pp. 33-37.
Matheis et al., "The Role of the Adsorption Process for Production and Control Combined Adsorbed Vaccines," Vaccine, 2002, vol. 20, pp. 67-73.
Morbidity and Mortality Weekly Report (MMWR), 1998, vol. 47, No. 1, pp. 12, 19.
Morefield et al. Distribution of adsorbed antigen in mono-valent and combination vaccine, Vaccine 27: 1973-1984 (2004). *
Morefield, G.L.. et al., "Distribution of adsorbed antigen in mono-valent and combination vaccines", Vaccine, 22 (15-16):1973-1984 (2004).
Remington: The Science and Practice of Pharmacy, 2000, 20th Edition, Lippincott Williams & Wilkins, ISBN:0683306472.
Summons to attend oral proceedings, dated Dec. 11, 2015, filed during examination of EP2652511, 9 pages.
Telford et al., "Gene Structure of the Helicobacter pylori Cytotoxin and Evidence of Its Key Role in Gastric Disease," J. Exp. Med., 1994, vol. 179, pp. 1653-1658.
The Molecular Probes Handbook-A Guide to Fluorescent Probes and Labeling Technologies, 2010, 11th Edition, Invitrogen.
The Molecular Probes Handbook—A Guide to Fluorescent Probes and Labeling Technologies, 2010, 11th Edition, Invitrogen.
Thiele, G.M. et al., "An enzyme-linked immunosorbent assay for the detection of antitetanus toxoid antibody using aluminum-absorbed coating antigen", J. Clin. Lab. Anal., 4(2): 126-129 (1990).
Treanor et al., "Evaluation of a Recombinant Hemagglutinin Expressed in Insect Cells as an Influenza Vaccine in Young and Elderly Adults," J. Infect. Dis., 1996, vol. 173, pp. 1467-1470.
Tummuru et al., "Cloning and Expression of a High-Molecular-Mass Major Antigen of Helicobacter pylori: Evidence of Linkage to Cytotoxin Production," Infect. Immun., 1994, vol. 61, pp. 1799-1809.
Ugozzoli, M. et al., "Flow cytometry: An alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant", Anal. Biochem., 418(2):224-230 (2011).
Vaccine Design-the Subunit and Adjuvant Approach, 1995, Springer, ISBN:030644867X.
Vaccine Design—the Subunit and Adjuvant Approach, 1995, Springer, ISBN:030644867X.
Zhu et al. Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA). Journal of Immunological Methods 344: 73-78 (2009). *
Zhu, D. et al., "Development of a Direct Alhydrogel Formulation Immunoassay", J. Immunol. Methods, 344(1): 73-78 (2009).
Zhu, D. et al., "Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines", Vaccine, 27(43): 6054-6059 (2009).

Also Published As

Publication number Publication date
US20130330840A1 (en) 2013-12-12
EP2652511B8 (en) 2017-06-28
WO2012082914A1 (en) 2012-06-21
ES2630029T3 (en) 2017-08-17
EP2652511B1 (en) 2017-04-05
EP2652511A1 (en) 2013-10-23

Similar Documents

Publication Publication Date Title
US9618508B2 (en) Flow cytometry analysis of materials adsorbed to metal salts
Smith et al. Immunogenicity of a DNA vaccine candidate for COVID-19
US10088481B2 (en) Methods for liquid direct fluorescent antibody intracellular virus detection
Chatel et al. Domain topology of nucleoporin Nup98 within the nuclear pore complex
JP6368224B2 (en) Efficacy test for vaccine preparations
EP2618148B1 (en) Time-resolved fluorescence energy transfer (TR-FRET) assay for detecting exposure to an infectious organism
US20120202191A1 (en) Detection method based on time resolved real time fluorescent energy transfer (tr-fret)
US20200080981A1 (en) Potency test for vaccine formulations
AU2021312381A1 (en) COVID-19 mucosal antibody assay
Leekha et al. Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters
Thakkar et al. Methods to prepare aluminum salt-adjuvanted vaccines
EP4245316A1 (en) Adjuvant containing zinc aluminum risedronate, and application thereof
TW201929896A (en) Comprehensive vaccine design for commensal disease progression
US20160103130A1 (en) Anti-measles cancer immunotherapy
Bisht STUDIES ON THERMOSTABILITY AND IMMUNOADJUVANTICITY OF PPR VACCINE VIRUS ENCAPSULATED IN MESOPOROUS SILICA NANOPARTICLES
Massadeh et al. Investigation the Concentration Levels of Essential and Non-Essential Elements in Veterinary Vaccines by Inductively Coupled Plasma Mass Spectrometry
Sun et al. Development of IMBs-qPCR method for detection of foodborne Salmonella
HK1190314A (en) Immunogenic bordetella bronchiseptica compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., CALIFORNI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UGOZZOLI, MILDRED;REEL/FRAME:031223/0849

Effective date: 20130803

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS, INC.;REEL/FRAME:031226/0372

Effective date: 20130916

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS, S.R.L.;REEL/FRAME:031223/0956

Effective date: 20130819

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SKIBINSKI, DAVID;LAERA, DONATELLA;NUTI, SANDRA;SIGNING DATES FROM 20130729 TO 20130814;REEL/FRAME:031223/0662

AS Assignment

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS AG;REEL/FRAME:038982/0913

Effective date: 20160615

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8